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METHOD DEVELOPMENT AND VALIDATION FOR THE QUANTIFICATION 
OF EIGHT SYNTHETIC PIPERAZINES IN BLOOD AND URINE USING 
LIQUID CHROMATOGRAPHY- TANDEM MASS SPECTROMETRY       
(UFLC-ESI-MS/MS) 
 
RAQUEL ALECIA LEBLANC 
ABSTRACT 
 Synthetic piperazines are chemically-produced compounds that contain a six-
member ring with two opposing nitrogen atoms.  Several piperazine derivatives, namely 1-
benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)-piperazine (TFMPP), and 1-(3-
chlorophenyl)-piperazine (mCPP), have fallen into the “designer drugs” category due to 
their increasing recreational use as a “legal” alternative to ecstasy (3,4-
methylenedioxymethamphetamine) (1-3).  These compounds share similar stimulant and 
physiological effects with amphetamines which make them desirable to young adults in 
party-type atmospheres (1, 4).  BZP, a Schedule I drug for its high abuse potential and no 
accepted medical use, is the only recreationally-abused synthetic piperazine currently 
federally controlled in the United States (5, 6).  
The purpose of this research was to develop and validate a reliable method to 
identify and quantify eight forensically significant synthetic piperazines in blood and urine 
using ultra-fast liquid chromatography-electrospray ionization-tandem mass spectrometry 
(UFLC-ESI-MS/MS).  The method was validated according to the Scientific Working 
Group for Forensic Toxicologists (SWGTOX) guidelines for quantitative analysis for both 
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matrices and includes the following analytes: 1-benzylpiperazine (BZP), 1-(4-
fluorobenzyl)-piperazine (FBZP), 4-methyl-1-benzylpiperazine (MBZP), 1-(4-
methoxyphenyl)-piperazine (MeOPP), 1-(para-fluorophenyl)-piperazine (pFPP), 1-(3-
chlorophenyl)-piperazine (mCPP), 2,3-dichlorophenylpiperazine (DCPP), and 1-(3-
trifluoromethylphenyl)-piperazine (TFMPP).  
All samples were prepared by fortifying 100 µL of certified drug-free whole blood 
and urine (UTAK Laboratories, Inc., Valencia, CA, U.S.A.) with certified reference 
standards (Cayman Chemical, Ann Arbor, MI, U.S.A.) of each analyte at desired 
concentrations and standard additions of 1-benzylpiperazine-d7, 1-(3-chlorophenyl)-
piperazine-d8, and 1(-3-trifluoromethylphenyl)-piperazine-d4 internal standards 
(Cerilliant, Round Rock, TX, U.S.A).  After pretreatment with 1 mL phosphate buffer, 
samples underwent solid phase extraction (SPE) on mixed-mode copolymeric columns 
(Clean Screen®, UCT Inc., Levittown, PA, U.S.A.). Eluents were evaporated to dryness 
with low heat (65°C) and nitrogen gas. Samples were reconstituted with a 50:50 mixture 
of methanol and 2mM ammonium formate buffer with 0.2% formic acid before being 
analyzed by a UFLC (Shimadzu Corporation, Kyoto, Japan) and 4000 QTRAP ESI-
MS/MS (SCIEX, Framingham, MA, U.S.A.) system.  Analyses were performed with 
multiple reaction monitoring scans in positive ionization mode using ions and voltages 
obtained from a manual compound optimization.  Analytes were separated on a reversed-
phase column (Kinetex® F5, Phenomenex®, Torrance, CA, U.S.A.) with a binary gradient 
consisting of a 2mM ammonium formate buffer with 0.2% formic acid and methanol with 
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0.1% formic acid.  The flow rate was 0.400 mL/min.  Analyst™ (SCIEX) software was 
used for data collection and MultiQuant™ (SCIEX) software was used for quantitation.   
The total run time was 11.5 minutes with equilibrations.  All calibration curves in 
both matrices exhibited R2 values > 0.99 using a weighting factor of 1/x.  A linear dynamic 
range of 20-2000 ng/mL was used for all analytes in both matrices, except for BZP in urine 
which ranged from 50-2000 ng/mL.  In blood, the limit of quantitation was 10 ng/mL for 
mCPP and TFMPP and 20 ng/mL for BZP, FBZP, MBZP, MeOPP, pFPP and DCPP.  In 
urine, the limit of quantitation was 10 ng/mL for MeOPP, mCPP, TFMPP and DCPP, 20 
ng/mL for FBZP, MBZP and pFPP and 50 ng/mL for BZP.  When a 200 ng/mL 
concentration was evaluated, the SPE procedure showed percent recoveries ranging from 
80-95% for blood; except for BZP, FBZP, and MeOPP which had recoveries of 60%, 60%, 
and 105%, respectively.  Percent recoveries ranged from 82-94% for urine; except for BZP 
and FBZP which had recoveries of 66% and 68%, respectively.  Bias and precision were 
assessed at concentrations of 50, 200, and 700 ng/mL.  All samples were calculated within 
±20% bias and within ±20% coefficient of variation.  The highest concentration evaluated 
that did not produce carryover in subsequent matrix blanks was 5000 ng/mL. Ionization 
was suppressed for all analytes in both matrices by 45-95%.  Matrix effects were present 
but were determined to be insignificant. Of the drugs evaluated, caffeine, 
dibenzylpiperazine, and 1-(4-chlorophenyl)-piperazine (pCPP) produced chromatographic 
peaks in the method; however, pCPP was the only substance that affected quantitation of 
an analyte. It increased the peak area of mCPP by almost 50% when present at the same 
concentration which suggests this method is unable to differentiate between isomeric pairs.  
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This is a sensitive, reliable, and robust method with a wide linear dynamic range to 
account for the presence of these analytes in both blood and urine.  This research will 
provide for the identification and quantitation of these substances in forensic casework.  
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1. INTRODUCTION 
1.1 Chemistry and Background   
 Synthetic piperazines are a class of man-made derivatives and analogs of the 
piperazine molecule.  Piperazine is a non-aromatic six-member ring, which contains two 
nitrogen atoms located on opposing ends of the ring.  The synthetic piperazine derivatives 
typically contain structural “add-ons” such as aromatic rings, halogens, and methyl- and 
methoxy- functional groups.  Although the acid dissociation constants of many synthetic 
piperazines are unknown, these molecules are basic in nature with the piperazine group 
having an acid dissociation constant (pKa) of 9.8 (7).  A variety of commonly used 
prescription medications are piperazine derivatives.  These medications include 
antipsychotics, such as clozapine and olanzapine, anti-depressants, like trazodone and 
nefazodone, and anti-histamines, such as buclizine and meclizine (8, 9).  Sildenafil and 
vardenafil are also piperazine derivatives and are used to treat erectile dysfunction (8, 9). 
Certain synthetic piperazines have gained attention throughout the world for their 
psychoactive stimulant properties as well as their use in “rave” scenes (2, 10). 
 
1.2 Recreational Use  
1.2.1 Synthetic Piperazines as “Designer Drugs” 
 Designer drugs, also known as new psychoactive substances, are drugs that have 
been synthesized to provide a desired psychological effect, typically similar to that of a 
federally controlled drug (1, 3). Since most are relatively new to the drug market and have 
not yet been regulated under drug control laws, many of these designer drugs are legal to 
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possess, distribute and consume in many different countries (9).  Therefore, they are often 
marketed as being a legal form of the drug they are designed to imitate (9, 11).  Once 
restrictions are placed on the new designer drug, illegal drug manufacturers may slightly 
tweak the chemical structure and synthesize a modified version of the drug (1, 11).  By 
doing so, its desired physiological effects are similar and it has once again evaded 
governmental drug-control (11).  
Over the past two decades, a small panel of synthetic piperazines has fallen into the 
“designer drugs” category.  These substances, namely 1-benzylpiperazine (BZP), 1-(3-
trifluoromethylphenyl)-piperazine (TFMPP), and 1-(3-chlorophenyl)-piperazine (mCPP), 
have become more well-known due to their popularity as recreational “party” drugs that 
elicit physiological responses similar to those of 3,4-methylenedioxymethamphetamine 
(MDMA) and other amphetamine-type stimulants (3, 4, 9, 12).  Currently, BZP is the only 
recreationally abused synthetic piperazine that is federally controlled by the United States 
(5, 6, 13).  This means structural analogs that have been more recently appearing in drug 
markets are not legally prohibited.  Thus, their legal status and euphoric stimulant 
properties make them advantageous for drug users, especially young adults (1, 10, 14).  
 
1.2.2 History and Scheduling 
 BZP was first developed by Wellcome Research Laboratories in the United 
Kingdom in 1944 (1, 13, 15).  It was originally researched as an anti-parasitic drug for 
cattle in the mid 1940’s to 1950s and subsequently researched by the same company as an 
anti-depressant in the 1970’s (9).  Further research demonstrated that it had strong potency 
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and amphetamine-like effects in animals (5, 9, 16).  Due to the high concern for public 
health and safety, it was never patented or used for medical purposes (5).  BZP reappeared 
in the United States in California in 1996, this time as a recreational drug having a similar 
appearance to “ecstasy” pills (5, 13).  Drug seizures showed that the use of BZP had quickly 
spread throughout the country, covering many of the coastal states (5).  Seizures also 
showed the addition of TFMPP to these BZP-containing drugs around the year 2000 (5). 
In September of 2002, BZP and TFMPP were temporarily added to the Controlled 
Substances Act as Schedule I drugs under emergency placement by the Drug Enforcement 
Administration (DEA) (1, 5).  After thorough review of the drug’s distribution and sale 
patterns, abuse patterns and relevant scientific data, BZP was permanently placed in the 
Schedule I of the Controlled Substances Act (5).  This ruling became effective on March 
19, 2004 (5, 13).  Through research, the DEA and Department of Health and Human 
Services concluded that BZP does not have an accepted medical use in the United States, 
has not been deemed safe for use under medical supervision and has a high potential for 
abuse which could result in physical dependence (5).  However, it was also concluded that 
there was insufficient data to prove that TFMPP caused dependence or posed a significant 
health threat to users (5).  Therefore, TFMPP was removed from the Controlled Substances 
Act in March of 2004 (1, 5).  It is no longer a scheduled drug in the U.S., except in Florida 
where it is under state rule as a schedule I drug (6, 17).  
 Other benzyl- and phenyl- piperazines have also entered the global drug market in 
recent years due to increasing and tighter controls of BZP throughout the world (2).  These 
piperazine derivatives include 1-(3,4-methylenedioxybenzyl)-piperazine (MDBP), 4-
4 
bromo-2,5-dimethoxy-1-benzylpiperazine (2C-B-BZP), 4-methyl-1-benzylpiperazine 
(MBZP), 1-(4-fluorobenzyl)-piperazine (FBZP), dibenzylpiperazine (DBZP), 
methylphenylpiperaznie (MPP), chlorophenylpiperazine (CPP), 1-(4-fluorophenyl)-
piperazine (pFPP), 1-(4-methoxyphenyl)-piperazine (MeOPP), and 2,3-
dichlorophenylpiperazine (DCPP) (9, 18).  Mostly prevalent in New Zealand, United 
Kingdom, United States, Canada, Germany, Sweden and Japan, these drugs are commonly 
sold as “party pills” or “ecstasy” and may be found individually or in combination with 
each other (1, 3, 9, 19, 20). 
None of these new designer piperazine derivatives, with the exception of BZP, are 
federally regulated in the United States and none (including BZP) have been approved for 
human consumption by the Food and Drug Administration as of 2016 (6, 21).  In terms of 
state law, Florida is currently the only state that prohibits the use of certain designer 
piperazines.   Under the 2015 Florida Statute, BZP, pFPP, CPP, MPP, MeOPP, DBZP and 
TFMPP are listed as Schedule I drugs, making it a felony to traffic, possess, or consume 
them within state borders (17).   
 
1.2.3 Marketing, Use and User Demographics   
 Recreationally used synthetic piperazines are typically sold as small brightly 
colored tablets or capsules (20, 22).  In this preparation, the active component(s) is in the 
form of a hydrochloride salt.  Tablets may be circular or pressed in various shapes.  The 
tablet’s surface may be imprinted with a logo or figure, such as a symbol, television 
character or an animal (20, 23).  Although they are most commonly ingested as pills, they 
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may also be purchased as a white powder or greenish-yellow liquid (24).  Liquid 
preparations may include the use of the active component(s) in the form of a free base or 
the user emptying the contents of a capsule into a drink (9, 10).  The use of the free base 
form is rare due to the high pH that is corrosive and may cause burns or tissue damage (9, 
13).   Aside from oral ingestion, other routes of administration include nasal insufflation 
and smoking (10, 13).  
 A typical dose ranges from 20 mg to 200 mg, or one to three pills (10, 13, 22).  Two 
studies that reviewed emergency department records in New Zealand reported that adverse 
effects of synthetic piperazine intake were occurring after the ingestion of an average of 
3.9 pills and 4.5 pills (2, 25).  These drugs can be purchased from the internet, smart shops 
and street dealers and are often marketed as “party pills”, “legal highs”, “legal ecstasy”, 
“safe highs” or “herbal highs” to attract consumers (1, 2, 9, 19). Street names for various 
piperazines or combinations include “A2”, “Frenzy”, “Nemesis”, “Bliss”, “Charge”, 
“Rapture”, “legal E”, “Mash”, “legal X”, “Molly”, and “Ecstasy” (1, 23, 26).  A study done 
in New Zealand in 2007 found that the cost for a “pack” of pills sold on the internet ranged 
from $10 to $60 (10).  
Pills may contain a wide variety of active components, diluents, impurities, and 
adulterants. They are often prepared with different ratios and combinations of synthetic 
piperazines, as well as other active components to fulfill consumer needs (26).  For 
example, synthetic piperazines are often seen in combination with caffeine, procaine, 
herbal extracts and MDMA (9, 19, 20).  DBZP is a known impurity of BZP synthesis and 
has been observed in seized drug samples in lower concentrations (9, 15).  More recently, 
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BZP has been completely substituted by MBZP, an analog that is less potent but still 
marketed as BZP (19).  Additionally, synthetic piperazines have been used as adulterants 
for amphetamines and cocaine (3).  
 The majority of consumers are young adults, typically between ages 18-29 and an 
average age of 23 (1, 2, 9, 10).  These substances are commonly used at music festivals, 
raves, nigh-clubs, and other party-type atmospheres (1, 9, 23).  The euphoric stimulant 
effects of these drugs provide users with the energy to stay dancing and in a “feel good” or 
social mood for long periods of time (10).  These drugs are attractive to individuals with 
an existing stimulant dependence, that have abused MDMA in the past, who are looking 
for a “safer” or “legal” alternative to MDMA, or who commonly attend rave scenes (1, 9, 
12, 13).  Studies have shown that new users are most often introduced to these substances 
or peer pressured into taking them through friends and relatives (10).  Some users have 
also reported using party pills before work to stay awake or to help them stay focused on 
certain tasks such as chores and studying for school examinations (10).  
 
1.2.4 Poly-Drug Use 
 As previously mentioned, a single pill of ecstasy or party pills may contain a variety 
of substances.  For example, the substances may be of a similar type, such as pills that 
contain multiple synthetic piperazines in one dose (3).  The most common combination of 
designer synthetic piperazines is BZP and TFMPP and the ratios of these compounds tend 
to differ between products (1, 9).  One drug, called “X4” claims to contain four different 
synthetic piperazines in each pill (3).  Drug seizures showed that some pills contained 
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MDMA with a designer piperazine (1, 20).  Other added substances may not be the primary 
ingredient but may still elicit a physiological response (19).  These substances, also known 
as adulterants, are often added to dilute the drug of interest so that more product can be 
distributed (27).  Typical adulterants seen with synthetic piperazines include lidocaine, 
procaine, acetaminophen, dextromethorphan and caffeine (20, 24).  Due to the large variety 
of drug concentrations and active components between purchased products, effects are 
often extremely unpredictable (9).  Also, many users are unaware of the components in the 
drugs they are taking, meaning that that are also unaware of the health risks associated with 
the drugs (10).  
Individuals may take more than one type of drug.  Drugs that are used in 
combination with piperazine pills or powders include alcohol, cannabis, amphetamines, 
cocaine, ketamine and nicotine (2, 10, 24).  These are all substances commonly abused at 
night-scenes, such as parties and clubs.  The use of synthetic piperazines with other drugs 
can be dangerous and have caused adverse effects in users (16).   
 
1.3 Pharmacology of Designer Synthetic Piperazines  
 Since many of these designer drugs are relatively new, they have not been 
extensively studied.  Many of the pharmacological properties, such as absorption rates, 
metabolism, excretion, biochemical interactions, potency, and psychological effects, 
remain unknown (1, 9).  Of all the designer synthetic piperazines, BZP, TFMPP, and mCPP 
have been studied the most in terms of their pharmacodynamic and pharmacokinetic 
characteristics.   
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1.3.1 Pharmacodynamics  
1.3.1.1 BZP 
 Pharmacodynamics is the study of a drug’s impact on the body (28). On a molecular 
level, benzyl-piperazines, such as BZP, have demonstrated amphetamine-like stimulant 
effects in the central nervous system (1, 12).  It has been found that BZP inhibits the 
reuptake of dopamine due to the release of 1-methyl-4-phenylpyridin ions that bind to 
dopamine transporters (12, 14, 16).  The blockage of dopamine transporters and the 
promotion of dopamine release from neurotransmitters cause an increase in dopamine in 
the nucleus accumbens, an area of the brain that contributes to mood, learning, and the 
body’s reward system (1, 11, 12, 16).  To a lesser extent, BZP will also cause an increase 
in serotonin and noradrenaline in the central nervous system (1, 11, 14, 22, 25).  
These chemical changes in the brain result in a stimulated response of the central 
nervous system and cardiovascular system (11).  Users may experience an increase in heart 
rate, blood pressure, and locomotion (1, 25).  It may take up to two hours before the onset 
of effects and effects typically last six to eight hours (1).  It is roughly 10 to 20 times less 
potent than amphetamine, but may still cause a dependence in users (13, 29).  Additional 
physiological effects of BZP use may include confusion, anxiety, severe changes in mood, 
insomnia, headaches, and paranoia (1, 10, 25).  Adverse effects, typically brought on when 
the user ingests a larger dose than what is suggested, may include nausea, vomiting, 
palpitations, hyponatremia, seizures, collapse, acute renal failure, and acute psychosis (1, 
25).  BZP alone does not produce hallucinations (1).  Although studies show it is less potent 
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than amphetamines, it should not be perceived as a safe alternative as life threatening 
conditions have been observed.  
 
1.3.1.2 TFMPP 
 TFMPP binds to serotonin receptors and to serotonin transporters which enhances 
the release of serotonin from neurons (1, 12, 14).  These actions together produce an 
increase in extracellular serotonin in the nucleus accumbens (1, 12, 14).  TFMPP does not 
increase levels of dopamine, norepinephrine, or noradrenaline in the central nervous system 
(12, 14, 16).  The serotonergic activity in the brain produces visual or auditory 
hallucinations and decreased locomotion (1, 4).  Studies suggest that TFMPP does not 
cause a physical dependence in individuals and it was determined to be three times less 
potent than MDMA (1, 12).  
  
1.3.1.3 BZP/TFMPP in Combination  
 Studies have demonstrated that BZP and TFMPP, when used in combination, elicit 
responses similar to those of MDMA (4, 12).  MDMA produces its effects by releasing 
both dopamine and serotonin through dopamine and serotonin transporters (4, 12, 14).  The 
increased dopamine levels caused by BZP and the increased serotonin levels caused by 
TFMPP results in euphoria, hallucinations, increased heart rate, and an increase in attention 
and energy (1, 14, 16).  However, the co-administration of these drugs in mice caused 
seizures, which suggests that a dangerous synergism exists between the drugs (14, 16).  
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1.3.1.4 mCPP 
 Also being a phenyl-piperazine, mCPP exerts its effects in a similar fashion to 
TFMPP.  Rather than non-selectively binding to serotonin receptors, it only binds to certain 
receptors while exhibiting antagonist traits, or partial agonist traits at other serotonin 
receptors (1, 30).  However, studies have demonstrated that it is a strong serotonin reuptake 
inhibitor (1, 30).  In addition, mCPP also binds to serotonin transporters inducing the 
release of serotonin from neurotransmitters resulting in a rise in extracellular serotonin 
levels (1, 30).  The administration of mCPP to mice also showed an increase in dopamine 
and norepinephrine levels, but to a lesser extent than the observed serotonin release (30).   
The biochemical interaction may result in physiological effects such as hallucinations, 
nausea, dizziness, anxiety, intense panic attacks, and severe headaches (1). 
 
1.3.2 Pharmacokinetics 
1.3.2.1 BZP 
 Pharmacokinetics is the study of a drug’s movement and time course within the 
body (28). BZP and other piperazine derivatives are absorbed in the gastrointestinal tract 
after ingestion (1).  BZP is not extensively metabolized; however, metabolites that can be 
detected in urine and plasma at low concentrations include 4-hydroxy-BZP and 3-hydroxy-
BZP (1, 26, 31).  A study performed in 2009 demonstrated that the absorption half-life is 
6.2 minutes and the elimination half-life is 5.5 hours (31).  Unchanged BZP can be detected 
in plasma for up to 30 hours after the substance is ingested and is excreted as 6% of the 
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original dose (1, 31).  Metabolites are only excreted as 0.11% of the original dose (1, 31).  
BZP is also an active metabolite of other piperazine drugs, such as piberaline (29).  
 
1.3.2.2 TFMPP 
 TFMPP is also readily absorbed in the gastrointestinal tract, with an absorption 
half-life of 24.6 minutes (1).  TFMPP is extensively metabolized, with the major metabolite 
being 4-hydroxy-TFMPP (1, 26).  Unchanged TFMPP may go undetected in urine since 
less than 1% of the total dose is excreted in this form (1, 26).  Many metabolites, including 
hydroxy-TFMPP are thought to undergo conjugation and be excreted as N-glucuronide (1). 
 
1.3.2.3 mCPP 
 Similar to TFMPP, mCPP is readily absorbed in the gastrointestinal tract and is 
extensively metabolized (1).  The major metabolite is para-hydroxy-mCPP (1).  Although 
it is severely metabolized, the unchanged drug can still be detected at low concentrations 
in urine (1).  mCPP is also a metabolite of some therapeutic drugs, such as trazodone, 
nefazodone, etoperidone and mepiprazol (1, 29).  
 
1.4 Current Detection Methods  
 A variety of screening methods for the presumptive identification of these 
compounds have been published.  Synthetic piperazines have been tested with various color 
tests and immunoassays; however, there is no currently accepted color test or immunoassay 
specific to synthetic piperazines (1, 9).  False positives with these tests have been known 
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to occur, predominantly when tested using methods for identification of amphetamine-type 
compounds (1, 9).  Because of this, the most commonly used screening methods 
incorporate chromatographic separation, such as with a gas chromatograph (GC), liquid 
chromatograph (LC) or high performance liquid chromatograph (HPLC), followed by 
detection by a diode array detector (DAD), flame ionization detector (FID), nitrogen-
phosphorus detector (NPD), or mass spectrometer (MS).  Described instrumental screening 
methods include the use of HPLC/DAD, HPLC/FID, GC/NPD, GC/MS, and HPLC/MS 
systems (9, 32, 33).  Sample preparations for chromatographic screening methods include 
“dilute and shoot”, where the specimen is solely diluted before injection onto the 
instrument, liquid-liquid extraction, and solid phase extraction (9, 32, 33).  A derivatization 
step was employed in many of the GC-MS methods that have been published to allow for 
better analyte separation (9).   
 The number of confirmatory and quantitative methods are minimal and tend to be 
limited to the analysis of BZP and TFMPP (8, 9, 34).  They are also mostly limited to the 
analysis of urine specimens and, in some cases, plasma (8, 9, 24, 26, 29, 31, 33, 35).  
Existing methods differ in terms of the sample preparation procedure employed, the 
internal standards used, and the actual method parameters or analytical columns used (8, 
9, 24, 26, 29, 31, 33, 35).  Although the chemistries of the columns differ between methods, 
they are all types of reverse-phase columns.  Sample preparations for confirmation methods 
mostly included liquid-liquid extractions and solid phase extractions and confirmation 
methods mostly used some type of GC-MS or LC-MS instrumentation.  
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1.5 Research Objectives 
If the distribution and use of synthetic piperazine drugs continue, governmental 
agencies may decide to control or regulate the use of these substances.  This would result 
in the need for a reliable, confirmatory, and quantitative method to detect these drugs in 
forensic case specimens submitted for toxicological analyses.  Furthermore, if BZP and 
TFMPP remain controlled substances in various countries, the use of other piperazine 
derivatives may be observed more frequently.  Therefore, a method to follow abuse patterns 
of synthetic piperazines may be helpful in maintaining public health and safety.  
The fundamental goal of this research was to develop a method that could 
accurately and reliably confirm and quantitate an array of synthetic piperazine drugs of 
abuse in both blood and urine.  This method exploits the sensitivity and resolving power 
of a liquid chromatograph-electrospray ionization-tandem mass spectrometer for the 
accurate and precise detection of BZP, TFMPP, MBZP, FBZP, MeOPP, pFPP, mCPP, 
DCPP, and TFMPP.  Quantitation was performed with deuterated internal standards of 
BZP, mCPP, and TFMPP.  The method was assessed in full accordance with the Scientific 
Working Group of Forensic Toxicologists (SWGTOX) Guidelines for Quantitative 
Methods (36).  This includes evaluation of the sample preparation procedure, detection and 
quantitation limits, carryover concentrations, a calibration model, bias, precision, 
extraction recovery, matrix effects, interferences, and ionization suppression/enhancement.  
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Figure 1: Chemical Structures. (A) Designer drugs BZP, FBZP, MBZP, MeOPP, pFPP, 
mCPP, DCPP and TFMPP. (B) Chemical structures of internal standards BZP-d7, mCPP-
d8, and TFMPP-d4 
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2. MATERIALS AND METHODS 
2.1 Theory of Instrumentation 
2.1.1 Liquid Chromatography 
 Liquid chromatography (LC) is the method of separating components of a mixture 
by exploiting their different affinities for a solid stationary phase and a liquid mobile phase 
(28).  The column is a cylindrical tube that houses the stationary phase and is where 
separation occurs.  Once the mixture is transferred to the column, a solvent or reagent is 
applied which helps to carry the analytes in the mixture through the column.  The individual 
analytes will separate as they travel through the column because they have unique 
intermolecular interactions with the liquid mobile phase and solid stationary phase.  These 
interactions cause the analytes to pass through the column at different rates and elute one-
by-one.  
Operating under the same principles, liquid chromatography systems are analytical 
instruments that utilize pumps to apply pressure and force the mobile phase through the 
stationary phase, resulting in a faster and more efficient separation (28).  Other components 
of LC systems include a solvent reservoir to house the mobile phase(s), a degassing unit to 
remove bubbles and dissolved gasses from the mobile phase(s), an auto sampler for 
automatic sample injection, a stainless steel column to house the stationary phase and a 
detector to detect the analytes and transfer data to a computer display for viewing. The type 
of mobile phase depends on the chemistry of the analytes that will be separated (28).  
Examples of mobile phases used in LC systems include methanol, acetonitrile, water, and 
buffers.  The type of stationary phase used is also dependent upon the chemistry of the 
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analytes but typically consists of a silica support and may have a modified surface to enable 
more specific interactions (28).  The molecular groups added to the surface of the silica 
include alkyl chains, aromatic rings, and polar groups.  The individual analytes separated 
by the mobile phase and stationary phase are often characterized by their retention time, or 
the time it takes an analyte to reach the detector after injection.  Data is then formulated as 
a chromatogram, or a plot of time versus intensity.  
 
2.1.2 Mass Spectrometry 
 Mass spectrometry is an analytical technique in which analytes become charged in 
the ionization source, are separated by their mass-to-charge ratios (m/z) by a mass analyzer, 
and detected by a detector (27).  Although different ionization sources exist, a common 
one in single mass spectrometer instruments is electron impact.  In this type, a stream of 
electrons is generated, typically from a tungsten filament, and aimed directly at the analytes 
as they enter the system through a high pressure vacuum (27).  A high energy collision 
occurs which breaks molecular bonds and results in an array of fragment ions (27).  Thus, 
fragmentation is the process of a molecule breaking down into smaller pieces.  During the 
collision process, a charge is applied to the fragments so they can be discriminated by the 
analyzer and be detected (27).  The signal of the ions is measured and data is transferred to 
a computer for viewing.  The data generated is in the form of a mass spectrum, or a plot of 
m/z versus intensity.  
 A tandem mass spectrometer (MS/MS) is two mass spectrometers in tandem with 
each other.  These systems often provide greater sensitivity and greater discriminating 
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power over single mass spectrometers (27).  Tandem mass spectrometers contain an 
ionization source, a mass analyzer, a collision cell, a second mass analyzer and a detector. 
Through this process, analytes are first transformed into gas-phase ions in the ionization 
source.  These “precursor” ions travel through the first mass analyzer where they are 
separated by their m/z.  They then enter a collision cell.  Here, the precursor ions collide 
with an inert gas and fragment.  This is followed by further m/z separation in the second 
mass analyzer and then detection by the detector (27).  There are several types of mass 
analyzers; however, typical tandem mass spectrometer systems use quadrupoles.  
Quadrupoles consist of four rods in a square formation.  Two of the rods are applied with 
direct current while the other two rods are applied with a radio frequency.  As these currents 
alternate and increase, only ions of a specific m/z can resonate with the current at a time. 
Only the ions that resonate with the current travel completely through the quadrupole (27).   
 
2.1.3 Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry   
 Mass spectrometers are often used in conjunction with chromatography 
instruments, acting as the detector for eluting analytes.  A liquid chromatograph-tandem 
mass spectrometer (LC-MS/MS) is one such example (27).  Here, a mixture of different 
analytes is injected into the LC component.  The mixture is immediately met with the 
mobile phase and carried through the column at high pressure where it is separated into its 
individual analytes.  A piece of plastic tubing connects the column to the ionization source 
of the mass spectrometer so eluents can flow directly from the column to the MS.  
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 Electrospray ionization (ESI) is one type of ionization.  Through this process, 
analytes, which are still in solution from the LC, travel through a high voltage probe that 
passes a charge onto the liquid (27).  As the charged liquid leaves the probe, it enters a low 
pressure, high temperature vacuum.  Pure, hot nitrogen gas is aimed onto the eluent to 
nebulize the liquid into a fine mist.  This facilitates the subsequent rapid evaporation of 
mobile phase, leaving only gas phase ions to enter the mass spectrometer (27).  Gas phase 
ions are accelerated by the application of several voltages throughout the MS so they have 
sufficient energy to travel through the first mass analyzer, fragment in the collision cell, 
and pass through the second mass analyzer to reach the detector (27).  
 
2.2  Materials  
2.2.1 Standards/Reagents  
Millipore water from a Synergy UV water filtration system from EMD 
Millipore/Merck (Darmstadt, Germany) was used throughout this study.  Liquid 
chromatography (LC) grade methanol, LC grade isopropanol, optima grade formic acid, 
optima grade acetonitrile, ammonium hydroxide, methylene chloride, concentrated 
hydrochloric acid, ammonium formate, anhydrous disodium phosphate (Na2HPO4), and 
monohydrate sodium dihydrogen phosphate (NaH2PO4· H2O), and caffeine were 
purchased through Fisher Scientific (Waltham, MA, U.S.A).  BZP, FBZP, MBZP, MeOPP, 
pFPP, mCPP, TFMPP, and DCPP were purchased from Cayman Chemical Company (Ann 
Arbor, MI, U.S.A.) as standards of 10 mg powder, except for BZP which was received as 
a 1 mg/mL standard in methanol.  The compound (-)-11-nor-9-carboxy-∆9-THC was used 
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during the interference study and was purchased from Cayman Chemical as a 1 mg powder.  
Deuterated internal standards (BZP-d7, mCPP-d8, and TFMPP-d4) were received as 100 
µg/mL standards in methanol from Cerilliant Corporation (Round Rock, TX, U.S.A.).  
Nicotine, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine 
(MDMA), 3,4-methylenedioxyamphetamine (MDA), hydrocodone, morphine, and 
alprazolam, which were all used for interference studies, were received as 1 mg/mL 
standards in methanol from Cerilliant. Powder forms of 1-(4-chlorophenyl)-piperazine 
(pCPP), acetaminophen and lidocaine, which were also used for interference studies, were 
purchased from Lipomed, Inc. (Cambridge, MA, U.S.A.), Sigma-Aldrich Corporation 
(Natick, MA, U.S.A.) and MP Biomedicals, LLC (Solon, OH, U.S.A.), respectively.    
 
Table 1: Lot Numbers of Certified Reference Materials. All certified reference 
standards were stored at -20ºC, with the exception of powder forms of acetaminophen, 
caffeine and lidocaine which were stored at room temperature (20ºC). 
 
Product Company  Lot Numbers 
(-)-11-nor-9-
carboxy-∆9-THC 
Cayman Chemical 0475400-5 
Acetaminophen Sigma-Aldrich SLBB2780V 
Alprazolam Cerilliant FE04161401 
Amphetamine  Cerilliant FE07011403 
Blood  UTAK B1086, B0786, B1027 
BZP-d7 Cerilliant FE06221504 
BZP Cayman Chemical 0470646-1, 0476703-1 
Caffeine Fisher Scientific 068176 
DBZP Cayman Chemical 0435856-35 
DCPP Cayman Chemical 0446497-12, 0446497-15 
FBZP Cayman Chemical  0435859-14, 0435859-19 
Hydrocodone Cerilliant FE05291404 
Lidocaine MP Biomedicals M7662 
MBZP Cayman Chemical  0465260-5, 0465260-6 
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Product Company Lot Numbers 
mCPP Cayman Chemical 0446996-11, 0446996-18 
mCPP-d8 Cerilliant  FN071111-01 
MDA Cerilliant  FE071612-02 
MDMA Cerilliant  FE043013-02 
MeOPP Cayman Chemical  0446981-9, 0446981-13 
Methamphetamine Cerilliant  FE082712-03 
Morphine Cerilliant FE03191402 
Nicotine Cerilliant FN091412-03 
pCPP Lipomed 1097.1B1.1 
pFPP Cayman Chemical  0435857-28, 0435857-30 
Plasma UTAK B1150 
Serum UTAK B1151 
TFMPP Cayman Chemical  0435854-32, 0435854-36 
TFMPP-d4 Cerilliant  FN08011407 
Urine UTAK B0683, B1085 
 
The pH meter used to verify the pH of mobile phases and reagents was an Oakton 
pH 700 meter from Fisher Scientific. Certified drug-free human whole blood, urine, serum, 
and defibrinated plasma were purchased from UTAK Laboratories, Inc. (Valencia, CA).  
Additional blood and urine used for testing was donated from the Federal Aviation 
Administration (Oklahoma City, OK, U.S.A.) and identified in this research as FAA-Case 
#5 (blood), FAA-Case #6B (blood), FAA-Case #6U (urine) and FAA-Case #7 (blood).  
Powder standards were weighed using a model PI-114 analytical balance from Denver 
Instrument (Bohemia, NY, U.S.A.). Further sample preparation was conducted on a solid 
phase extraction positive pressure manifold from UCT, Inc. (Bristol, PA, U.S.A.) and 
utilized Clean-Screen® DAU 200 mg/6mL solid phase extraction columns which are also 
from UCT, Inc. 
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2.2.2 UFLC-ESI-MS/MS Instrument Hardware and Software  
All analyses were conducted on a Shimadzu Prominence Ultra-Fast Liquid 
Chromatography System with LC-20AD model pumps and a SIL-20 AC model auto 
sampler (Kyoto, Japan). The chromatographic component was a Kinetex® F5 2.6µm, 
100Å, 150mm x 3.0mm ID column from Phenomenex, Inc. (Torrance, CA, U.S.A.).  
Analytes were detected on a SCIEX 4000 QTRAP tandem mass spectrometer consisting 
of a Turbo V™ electrospray ionization source (Framingham, MA, U.S.A.). Data was 
collected using Analyst® (version 1.6.2) software and quantitation was performed with 
MultiQuant™ 3.0 (version 3.05373.0) software (SCIEX).  Additional statistical analyses 
were performed using Excel (Microsoft Corporation, Redmond, WA, U.S.A.).  
 
2.3 Methods  
2.3.1 Compound/Source Optimization 
 Each analyte and internal standard was manually optimized via direct infusion into 
the mass spectrometer and data was viewed in real time through Analyst® software.  First, 
each reference standard was serially diluted to final concentrations of 100 ng/mL and 10 
ng/mL in a mixture of 50% millipore water, 49.9% methanol and 0.1% formic acid.  
Beginning with the 10 ng/mL concentration, the analyte of interest was loaded into a 1 mL 
syringe and all bubbles were removed.  The syringe was fastened to the syringe pump 
(SCIEX), connected to the ion source using PEEK tubing and infused at a starting rate of 
10 µL/minute with the mass spectrometer hardware profile activated.  
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In the “Manual Tune” mode in Analyst®, a “Q1 MS” scan in positive ionization 
mode was obtained to identify the precursor ion’s Q1 mass in Daltons (Da).  A range of 
approximately ± 50 Da around the analyte’s molecular weight was used as the mass scan 
range and a dwell time of 1 second was applied.  The “MCA” box was checked, the 
duration of the scan was set to 10 minutes and the scan was acquired. If the observed 
intensity in the total ion chromatogram was below 1e5, either the flow rate was increased 
to 50 µL/min or the concentration was increased to 100 ng/mL so that the intensity fell 
within the range of 1e5-1e7.  Once the signal was at an appropriate intensity and was stable 
in the total ion chromatogram, the Q1 mass was recorded.  The precursor ion was identified 
as being the peak in the extracted ion chromatogram that had a mass equal to the molecular 
weight of the analyte plus one due to the type of ionization that was applied.  
Without changing the infusion rate or analyte concentration, the scan type in 
Analyst® was changed to “Product Ion MS2”.  The “MCA” box was checked, and the 
previously determined Q1 mass was entered next to “product of”.  A mass scan range of 
50 to approximately 20 Da above the analyte’s Q1 mass was used and a dwell time of 1 
second was applied.  A collision energy ramp was applied to induce fragmentation.  The 
mass in Da of the three or four most intense product ion peaks in the extracted ion 
chromatogram was recorded.  These masses served as Q3 masses.  
The scan type was then changed to “MRM”, which stands for multiple reaction 
monitoring.  The previously determined Q1 and Q3 masses were entered into the MRM 
table and the dwell time was set to 150 msec.  The declustering potential (DP) ramp was 
applied and the scan was acquired three times.  The mean voltage maximum of the three 
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curves was recorded as the declustering potential. Next, the collision energy (CE) and 
collision cell exit potential (CXP) was determined for each product ion separately. To do 
this, only one Q1/Q3 mass was entered in the table at a time and the newly found 
declustering potential was added to the compound information window. A collision energy 
ramp was applied and the scan was acquired three times. The mean voltage maximum of 
the three curves was recorded as the collision energy for that product ion. This value was 
added to the compound information window and a cell exit potential ramp was applied. 
The scan was acquired three times. The apex with the greatest voltage in the curve was 
observed as the cell exit potential. The mean voltage of the three curves was recorded as 
the CXP for that product ion. The CE and CXP were determined for each product ion for 
that analyte. This procedure of determining the Q1 mass, Q3 masses, DP, CE, and CXP 
was repeated for all analytes and internal standards.   
Source optimization was performed by infusing BZP into a constant stream of 50% 
2mM ammonium formate buffer with 0.2% formic acid (mobile phase A) and 50% 
methanol with 0.1% formic acid (mobile phase B) at a flow rate of 0.400 mL/min.  BZP 
was prepared at 500 ng/mL in a 50% methanol 50% millipore water mixture, loaded into a 
1 mL syringe, fastened to the direct infusion syringe pump and attached to a tee connector 
via PEEK tubing which was attached to the ion source by PEEK tubing.  PEEK tubing 
from the output of the LC was attached to the tee connector as well.  The LCMS profile 
was activated.  In manual tune mode, the compound information for BZP was added to the 
MRM table.  The auto sampler was deactivated, the flow rate was set to 0.400 mL/min, 
and the pumps were set to output a mobile phase B concentration of 50%.  The source/gas 
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parameters were changed to the following starting conditions: curtain gas of 25, ion spray 
voltage of 5500, temperature of 450°C, source gas 1 of 50 and source gas 2 of 50. 
Horizontal and vertical micrometers were set to 5µm. The duration of the scan was set to 
20 min. With these parameters in place, the infusion pump was started at a flow rate of 10 
µL/min and the scan was acquired.  After the signal in the total ion chromatogram 
stabilized, the previously mentioned source/gas parameters were manipulated one at a time 
until the value that produced the best signal was obtained for each.  
 
2.3.2 LC-MS/MS Instrument Parameters 
 The compound and source-dependent parameters obtained from the previously 
described optimizations were used to build the LCMS acquisition method.  After the 
method was developed, analytes were prepared in both blood and urine and run on the 
instrument to determine the most intense product ions when present in the two matrices.  
The MRM table was narrowed down to the two most intense product ions per analyte and 
single most intense product ion per internal standard.  The most intense product ion, and 
the one that is used for quantitation, is labeled “1”.  The second most intense product ion, 
and the one used for analyte confirmation, is labeled “2”.  Table 2 shows the final MRM 
table used for all analyses, which were conducted in positive ionization mode.  The 
duration of the MRM scan was set to 6.5 minutes.  Refer to Table 3 for the optimized 
source/gas parameters. 
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Table 2:  MRM Table.  
 
Analyte 
Name 
Q1 
Mass 
(Da) 
Q3 
Mass 
(Da) 
Dwell 
Time 
(msec) 
DP 
(V)  
EP 
(V) 
CE 
(V) 
CXP 
(V) 
BZP-d7 IS 1 184.3 98.2 50 70.0 10 30.0 15.0 
BZP 1 177.1 91.1 50 66.0 10 32.0 14.0 
BZP 2 177.1 65.1 50 66.0 10 63.0 9.0 
FBZP 1 195.2 109.1 50 72.0 10 29.0 18.0 
FBZP 2 195.2 83.2 50 72.0 10 65.0 12.0 
MBZP 1 191.2 91.1 50 75.0 10 31.0 15.0 
MBZP 2 191.2 65.2 50 75.0 10 67.0 9.0 
MeOPP 1 193.2 150.2 50 70.0 10 28.0 24.0 
MeOPP 2 193.2 119.3 50 70.0 10 34.0 19.0 
pFPP 1 181.2 138.2 50 75.0 10 29.0 23.0 
pFPP 2 181.2 75.2 50 75.0 10 77.0 11.0 
mCPP 1 197.1 154.2 50 75.0 10 28.0 26.0 
mCPP 2 197.1 118.2 50 75.0 10 48.0 19.0 
mCPP-d8 IS 1 205.4 158.2 50 86.0 10 31.0 26.0 
DCPP 1 233.1 190.2 50 85.0 10 30.0 32.0 
DCPP 2 233.1 117.2 50 85.0 10 67.0 19.0 
TFMPP 1 231.1 188.1 50 80.0 10 32.0 33.0 
TFMPP 2 231.1 118.3 50 80.0 10 54.0 19.0 
TFMPP-d4 IS 1 235.4 190.2 50 84.0 10 32.0 32.0 
  
 
 
Table 3:  Optimized Ion Source/Gas Parameters.  The vertical and horizontal 
micrometers were set to 5 µm.  
 
Curtain 
Gas 
Collision 
Gas 
Ion Spray 
Voltage 
Temperature Ion Source 
Gas 1 
Ion Source 
Gas 2 
30 Medium 2500 600 50 80 
 
This method used 2mM ammonium formate buffer with 0.2% formic acid at pH 
2.69 as the aqueous phase (mobile phase A) and LC-grade methanol with 0.1% formic acid 
as the organic phase (mobile phase B). In the LC parameter settings, the maximum pressure 
was set to 5000 psi, the flow rate was set to 0.400 mL/min, and the starting condition was 
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5% mobile phase B. Auto sampler parameters were set to avoid contamination and are 
shown in Table 4.  
 
Table 4: Auto Sampler Settings  
Rinsing 
Volume 
Needle 
Stroke  
Rinsing 
Speed  
Sampling 
Speed 
Purge 
Time 
Rinse Dip 
Time 
Cooler 
Temperature  
1000 µL 52 mm 35 µL/sec 2 µL/sec 25 min 0 sec 15°C 
 
 The method begins with a 1.50 min pre-equilibration to ensure that the starting 
conditions are met with each run.  After a 5 µL sample injection, the % B concentration 
changes over time, as shown in Table 5.  After 6.5 minutes, the % B returns to the 5% 
starting condition and is held there for re-equilibration for approximately 3.5 minutes.   
 
Table 5:  LC Time Program.  
Time (min) Module Event Parameter (%) 
0.01 Pumps Pump B Concentration 5 
0.30 Pumps Pump B Concentration 5 
3.50 Pumps Pump B Concentration 80 
6.50 Pumps Pump B Concentration 80 
6.51 Pumps Pump B Concentration 5 
10.00 Controller Stop  
 
2.3.3 Sample Preparation  
 Powdered standards received from Cayman Chemical Company were individually 
prepared to 1 mg/mL stock solutions by weighing 1 mg of powder and diluting it in 1 mL 
of methanol.  These stock solutions were combined and diluted to make a 1 µg/mL stock 
solution (Stock 1).  Stock 1 was further diluted to make a 100 ng/mL stock solution (Stock 
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2).  These two stock solutions, consisting of all eight analytes, were used to prepare the 
calibrators, quality control (QC) samples and “unknowns” for the validation studies.  A 1 
µg/mL internal standard stock solution that consisted of the three deuterated internal 
standards (BZP-d7, mCPP-d8, and TFMPP-d4) was prepared by combining and diluting 
the 100 µg/mL standards obtained from Cerilliant.  The calibrators, prepared in glass test 
tubes, contained varying amounts of stock solution and 100 µL of matrix.  “Unknowns” 
were prepared in a similar fashion.  Every sample, except for double blanks, was fortified 
with 30 µL of the 1 µg/mL internal standard stock solution.  
 
Table 6: Preparation of Calibration Curve Samples. The table shows the quantity of 
each component used to prepare the calibration curve prior to solid phase extraction.  Stock 
1 was a 1 µg/mL solution and Stock 2 was a 100 ng/mL solution. Both stocks contained all 
eight analytes. The internal standard solution had a concentration of 1 µg/mL and contained 
the three deuterated internal standards. The matrix was either blood or urine. 
  
Calibrator/Sample 
Stock Solution 
(µL) 
Matrix  
(µL) 
Internal Standard 
Solution (µL) 
  Stock 1   
2000 ng/mL  200 100 30 
High QC (1500 ng/mL) 150 100 30 
1000 ng/mL  100 100 30 
500 ng/mL  50 100 30 
200 ng/mL 20 100 30 
 Stock 2   
50 ng/mL  50 100 30 
Low QC (50 ng/mL) 50 100 30 
20 ng/mL  20 100 30 
Negative Control  N/A 100 30 
Double Blank  N/A 100 N/A 
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 Solid phase extraction (SPE) was performed on all samples for the removal of 
unwanted matrix components and for the concentration of analytes.  Prior to SPE, each 
sample was pretreated with 1 mL of 100 mM phosphate buffer (pH 6) and was vortexed 
for about five seconds.  Clean Screen® drugs of abuse columns were loaded onto a solid 
phase extraction positive pressure manifold rack (UCT Inc., Levittown, PA, U.S.A.) and 
were conditioned by 1 mL methanol, followed by 1 mL 100 mM phosphate buffer (pH 6).  
Each was allowed to pass through the column via gravity flow only.  After elution of the 
buffer, samples were applied to the columns and were allowed to drip slowly only by the 
force of gravity.  The columns were subsequently washed with 1 mL of millipore water, 1 
mL 0.1 N hydrochloric acid and LC grade methanol.  Approximately 3 psi of pressure was 
applied to aid with the elution of each solvent/reagent.  Once complete, approximately 40 
psi of pressure was applied to the columns for five minutes to completely dry the sorbent.  
Samples were eluted from the SPE columns into clean glass test tubes using a base 
elution solvent with a pH of approximately 11.  This base elution solvent mixture consisted 
of 77% methylene chloride, 20% 2-propanol, and 3% ammonium hydroxide and was 
prepared fresh for every experiment.  After samples eluted via gravity flow, the test tubes 
were stored in a heating block until the solvent completely evaporated and the samples 
were dry.  The temperature of the heating block did not exceed 65ºC.  Occasionally, pure 
compressed nitrogen was passed over the test tubes to speed up the evaporation process.  
To further prepare for analysis, samples were reconstituted with 250 µL of a 50: 50 
mixture of 2mM ammonium formate buffer containing 0.2% formic acid and LC-grade 
methanol.  They were loaded into auto sampler vials containing inserts and positioned in a 
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tray within a cooled auto sampler chamber (15ºC).  All samples were run using the 
previously described LC-MS/MS method.  
 
2.3.4 Method Validation 
 Validation studies for quantitative analyses were performed in accordance with 
SWGTOX guidelines (36).  Data analysis was performed with MultiQuant™ software. 
BZP-d7 was used to quantify BZP, FBZP and MBZP; mCPP-d8 was used to quantify 
MeOPP, pFPP, mCPP, and DCPP; TFMPP-d4 was used to quantify TFMPP.  
 
2.3.4.1 Calibration Model/Limit of Quantitation/Carryover  
 The calibration model was developed by establishing the working range of 
concentrations for the calibration curve and evaluating the mathematical parameters so that 
concentrations of unknown synthetic piperazines in blood or urine could be accurately and 
reproducibly calculated.  This was first done by preparing samples at concentrations of 1, 
5, 10, 20, 50, 100, 200, 500, 1000 and 2000 ng/mL.  All items were further prepared by 
solid phase extraction, reconstituted and run on the LC-MS/MS.  Once the calibration 
model was developed, it was confirmed by re-preparing it and running it on the LC-MS/MS 
five times in both blood and urine.  Each calibration curve was modeled and assessed using 
MultiQuant™.  
With the calibration model in place, the limit of quantitation (LOQ) was determined 
for each analyte in each matrix.  This was done by preparing concentrations of 5, 10, 20, 
and 50 ng/mL.  Each concentration was prepared in triplicate for both blood and urine, 
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utilizing three different sources of blank matrix for each concentration.  Blank matrix 
samples B1086, B0786, and FAA-7 were used to examine the LOQ in blood and lot 
numbers B1085, B0683, and FAA-6U were used to examine the LOQ in urine.  Each 
sample was further prepared by solid phase extraction, reconstituted and run on the LC-
MS/MS three times.  Through the use of the calibration models, the calculated 
concentrations of the LOQ samples were examined for each run.  In this study, the limit of 
quantitation was defined as the lowest concentration that could be calculated within 20% 
accuracy in all three sources of blank matrix across all three runs.  
 A carryover assessment was performed to determine the highest concentration that 
could be run on the LC-MS/MS method without producing quantifiable analyte carryover 
in subsequent matrix blanks.  Concentrations of 3000 ng/mL, 3500 ng/mL, 4000 ng/mL, 
4500 ng/mL and 5000 ng/mL were prepared in both matrices, using lot number B1086 to 
prepare blood samples and lot number B0683 to prepare urine samples.  Additionally, a 
blank matrix sample (without internal standard) was prepared for both blood and urine. All 
samples were carried through solid phase extraction, reconstituted and run on the LC-
MS/MS.  High concentration samples were followed by the analysis of the blank matrix 
sample, and subsequently a solvent blank sample. The highest concentration that did not 
produce carryover in the blanks that followed was confirmed by running it three times. 
Again, blank matrix and solvent blank samples were analyzed after the high concentration 
sample. 
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2.3.4.2 Bias and Precision 
 Bias and Precision studies were conducted to examine the accuracy and 
reproducibility of the method when calculating the unknown concentrations of synthetic 
piperazines blood and urine samples.  “Unknown” samples with concentrations of 50, 200, 
and 700 ng/mL were evaluated.  Samples containing these concentrations were each 
prepared in triplicate for both matrices (18 samples total) using blank matrix B1086 for the 
blood specimens and B0683 for the urine specimens.  A calibration curve ranging from 20-
2000 ng/mL was also prepared, complete with negative controls, low and high QC samples, 
and a double blank.  All items were further prepared by solid phase extraction, 
reconstituted, analyzed by LC-MS/MS, and quantitated using MultiQuant™. Each 
“unknown” was run a total of five times.  Using the calculated concentrations from 
MultiQuant™, the grand mean and grand standard deviation across all samples and runs 
for each concentration were calculated in Excel.  The mean and standard deviation were 
also calculated between samples in a single run at each concentration.  From these values, 
the percent bias, the between-run percent coefficient of variation (CV) and the within-run 
percent coefficient of variation were calculated.  These calculations were made for each of 
the eight analytes at each concentration in each matrix.  The calculations used to determine 
these percentages are given below.  
 
𝐵𝑖𝑎𝑠 (%) = [
𝐺𝑟𝑎𝑛𝑑 𝑀𝑒𝑎𝑛 𝑜𝑓 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 − 𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
] × 100 
 
𝐵𝑒𝑡𝑤𝑒𝑒𝑛 − 𝑅𝑢𝑛 𝐶𝑉 (%) = [
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐺𝑟𝑎𝑛𝑑 𝑀𝑒𝑎𝑛 𝑓𝑜𝑟 𝐸𝑎𝑐ℎ 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝐺𝑟𝑎𝑛𝑑 𝑀𝑒𝑎𝑛 𝑓𝑜𝑟 𝐸𝑎𝑐ℎ 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
] × 100 
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𝑊𝑖𝑡ℎ𝑖𝑛 − 𝑅𝑢𝑛 𝐶𝑉 (%) = [
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑎 𝑆𝑖𝑛𝑔𝑙𝑒 𝑅𝑢𝑛 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒𝑠
𝑀𝑒𝑎𝑛 𝑜𝑓 𝑎 𝑆𝑖𝑛𝑔𝑙𝑒 𝑅𝑢𝑛 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒𝑠
] × 100 
 
2.3.4.3 Extraction Recovery  
An extraction recovery study was performed to determine the effects and efficiency 
of the solid phase extraction procedure on subsequent analyses. Concentrations of 50 
ng/mL and 200 ng/mL were assessed in both matrices. Blank matrix B1086 was used to 
prepare blood specimens and blank matrix B0683 was used to prepare urine specimens. 
Six samples were prepared for each of the two concentrations for each matrix (24 samples 
total).  To prepare the 50 ng/mL samples, 50 µL of the 100 ng/mL stock solution was 
pipetted into a test tube containing 100 µL of matrix. The 200 ng/mL samples were 
prepared by pipetting 20 µL of the 1 µg/mL stock solution into 100 µL of matrix in a test 
tube. In addition, 12 blank matrix samples were prepared for both blood and urine. Next, 
30 µL of the 1 µg/mL internal standard solution was pipetted into all samples, including 
blank matrix samples.  
All 48 samples were prepared by solid phase extraction.  After the elution of 
analytes into test tubes, six of the blank matrix blood samples and six of the blank matrix 
urine samples were fortified with 50 µL of the 100 ng/mL stock solution (for a 
concentration of 50 ng/mL).  Six of blank matrix blood samples and six of the blank matrix 
urine samples were fortified with 20 µL of the 1 µg/mL stock solution (for a concentration 
of 200 ng/mL).  All samples were evaporated to dryness, reconstituted, and analyzed by 
LC-MS/MS.  The recovery of analyte extracts as a percentage was calculated using the 
mean peak areas of the pre-extraction fortified samples and post-extraction fortified 
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samples for each concentration in both matrices. The equation below was used for these 
calculations.  
 
𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) = [
𝑀𝑒𝑎𝑛 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑃𝑟𝑒 − 𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐹𝑜𝑟𝑡𝑖𝑓𝑖𝑒𝑑 𝑆𝑎𝑚𝑝𝑙𝑒𝑠
𝑀𝑒𝑎𝑛 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑃𝑜𝑠𝑡 − 𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝐹𝑜𝑟𝑡𝑖𝑓𝑖𝑒𝑑 𝑆𝑎𝑚𝑝𝑙𝑒𝑠
] × 100 
 
2.3.4.4 Ionization Suppression/Enhancement  
 The effects of various matrices on analyte signal intensity was investigated at 
concentrations of 50 ng/mL and 1000 ng/mL.  This experiment incorporated two pristine 
whole blood specimens (UTAK Laboratories, lot numbers B1086 and B0786), three non-
pristine post-mortem blood specimens that had previously been treated with preservatives 
and may contain other drugs (Federal Aviation Administration, designated FAA-5, FAA-
6B, and FAA-7), two pristine urine specimens (UTAK Laboratories, lot numbers B1085 
and B0683), a non-pristine post-mortem urine specimen that may contain other drugs 
(Federal Aviation Administration, designated FAA-6U), a pristine plasma specimen 
(UTAK Laboratories, lot number B1150) and a pristine serum specimen (UTAK 
Laboratories, lot number B1151).   
A 50 ng/mL neat standard was prepared by adding 100 µL of the 100 ng/mL stock 
solution and 100 µL of a 50:50 methanol/millipore water mixture to an LC-MS/MS auto 
sampler vial.  A 1000 ng/mL neat standard was prepared by adding 100 µL of the 1 µg/mL 
stock solution to an auto sampler vial.  Next, 30 µL of the 1 µg/mL internal standard stock 
solution was added to both vials.  They were capped, vortexed and each run on the LC-
MS/MS six times.  Analyte-free matrix samples (without internal standard) were prepared 
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by adding 100 µL of matrix to a test tube. The ten matrix specimens were prepared in 
duplicate. All samples were further prepared by solid phase extraction. After elution into 
new test tubes, 50 µL of the 100 ng/mL stock solution was added to one set of the ten 
matrix specimens (for a concentration of 50 ng/mL) and 100 µL of the 1 µg/mL stock 
solution was added to the other set of ten matrix specimens (for a concentration of 1000 
ng/mL).  Then, 30 µL of the 1 µg/mL internal standard solution was added to all twenty 
samples.  They were dried to completion on a heating block, reconstituted with 250 µL of 
a 50:50 ratio of the mobile phases and run one time each on the LC-MS/MS.  
The mean peak area of the neat standard (set 1) was calculated for both 
concentrations.  The mean peak area of the ten matrix samples that were fortified post-
extraction (set 2) was calculated for both concentrations. The calculation used to determine 
percent ionization suppression or enhancement at each concentration is shown below.  
 
𝐼𝑜𝑛𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑆𝑢𝑝𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑟 𝐸𝑛ℎ𝑎𝑛𝑐𝑒𝑚𝑒𝑛𝑡 (%) = (
𝑀𝑒𝑎𝑛 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑆𝑒𝑡 2
𝑀𝑒𝑎𝑛 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑆𝑒𝑡 1 
− 1) × 100 
 
2.3.4.5 Interference Studies   
 Potential interferences from matrix components, internal standards, and other 
common analytes were explored. To determine if matrix interferences were present, 
analyte-free matrix samples (without internal standard) were prepared using the ten matrix 
sources from the ionization suppression/enhancement study. This was done by pipetting 
100 µL of matrix into test tubes, performing solid phase extraction, evaporating them to 
dryness, reconstituting them in 250 µL of a 50:50 mixture of the mobile phases, and 
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analyzing them by LC-MS/MS. The signal of the analytes was monitored to observe the 
presence or absence of false positive detections.  
 To study the effects of internal standards, two sets of samples were prepared using 
the ten different matrix sources. The first set consisted of 100 µL of matrix and 30 µL of 
the 1 µg/mL internal standard solution. The second set consisted of 100 µL of matrix and 
100 µL of the 1 µg/mL analyte stock solution to create a final analyte concentration of 
1000 ng/mL. No internal standard was added to set two. All samples underwent solid phase 
extraction, were reconstituted, and analyzed via LC-MS/MS. The signal of the analytes 
was observed in both sets to see if any stable isotopes posed as interferences within the 
method.  
 Other commonly encountered drugs were investigated to determine if they 
interfered with the method by causing false positives or by suppressing the signal of the 
analytes. The analytes involved in this study were amphetamine, methamphetamine, 3,4-
methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), 
(-)-11-nor-9-carboxy-delta9-tetrahydrocannabinol (carboxy-THC), nicotine, hydrocodone, 
morphine, alprazolam, caffeine, acetaminophen, lidocaine, 1,4-dibenzylpiperazine 
(DBZP), and 1-(4-chlorophenyl)-piperazine (pCPP).  If the standard was in the form of a 
powder, 1 mg was weighed and diluted in 1 mL of a methanol/millipore water (50:50) 
mixture to create a final concentration of 1 mg/mL.  Other standards were received as 1 
mg/mL solutions.  All standards were further diluted to 1000 ng/mL solutions and run 
individually on the LC-MS/MS. The signal of the analytes in the method was monitored 
for each run.  
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 To assess whether or not these drugs interfered with the signal of the analytes in 
the method, they were individually evaluated in the presence of the eight synthetic 
piperazines.  A 10 µg/mL stock solution containing all eight piperazines was prepared.  In 
a glass vial, 200 µL of the 10 µg/mL stock solution were combined with 2 µL of the 1 
mg/mL interference drug and 1798 µL of the 50% methanol/50% millipore water mixture. 
This produced a final concentration of 1000 ng/mL for all analytes. The contents were 
vortexed and 100 µL were transferred to a LC-MS/MS auto sampler vial along with 30 µL 
of the 1 µg/mL internal standard solution. The vial was capped and the contents were 
vortexed before being analyzed on the LC-MS/MS. This was done for each of the fourteen 
potential interference drugs. The signal was monitored and the peak area of the eight 
synthetic piperazines were compared to the mean peak area of the 1000 ng/mL neat 
standards run for the ionization suppression/enhancement study to see if there was any 
significant change in signal when in the presence of these drugs.  
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3. RESULTS  
3.1 Detection of Analytes  
 The method begins with a 1.50 minute pre-equilibration to ensure that the starting 
conditions are met with each run.  After sample injection, the 5% B concentration is held 
for 0.30 min to allow analytes to congregate before passing through the column.  This 
allows similar analytes to pass through the column closer together which results in 
narrower peaks in the chromatogram.  When this hold time was tested, both longer and 
shorter times resulted in broader peak shapes.  Since the piperazine compounds are very 
structurally similar and have similar molecular weights, they eluted at similar % B 
concentrations.  Therefore, a plateau was incorporated in the time program such that mobile 
phase B was held at a composition of 80% for three minutes.  This helped to increase the 
peak resolution.  After 6.5 minutes, the mobile phase composition changes to 5% B and is 
held there for 3.5 minutes before the next pre-run equilibration of 1.5 minutes.  This 4.5 
minute equilibration between runs provides sufficient time for column purging and for 
starting conditions to be met. 
 The total method length is 11.5 minutes and all analytes elute within 6.5 minutes. 
The three benzyl- piperazines elute first with retention times of about 3.82 min, 4.48 min, 
and 4.69 min for BZP, FBZP and MBZP, respectively.  The phenyl- piperazines elute with 
retention times of 5.09 min, 5.33 min, 5.80 min, 6.11 min, and 6.14 min for MeOPP, pFPP, 
mCPP, DCPP and TFMPP, respectively.  The deuterated internal standards mostly coelute 
with their non-deuterated counterparts and have retention times of 3.71 min, 5.80 min and 
6.15 min for BZP-d7, mCPP-d8 and TFMPP-d4, respectively.  DCPP and TFMPP were 
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unable to be separated.  All analytes were able to be identified with both fragments.  
Maximum ion ratio variance did not exceed ± 20%.  
 
Table 7: Mean, Standard Deviation and Percent Coefficient of Variation for Analyte 
Retention Times in Minutes. Ten matrix sources were fortified with the analytes at a 
concentration of 1000 ng/mL and each run once. The average retention time was calculated 
across these ten runs.  
 
Analyte Mean 
Standard 
deviation 
% CV 
BZP-d7 3.708 0.004 0.113 
mCPP-d8 5.797 0.005 0.082 
TFMPP-d4 6.146 0.005 0.074 
BZP 3.819 0.006 0.147 
FBZP 4.483 0.004 0.089 
MBZP 4.690 0.005 0.103 
MeOPP 5.093 0.005 0.091 
pFPP 5.334 0.005 0.099 
mCPP 5.800 0.005 0.086 
DCPP 6.112 0.005 0.078 
TFMPP 6.135 0.003 0.054 
 
Figure 2: Extracted Ion Chromatogram of a 1000 ng/mL Calibrator in Blood.  The x-
axis is time ranging from 0-6.5 min and the y-axis is intensity measured in counts per 
second (cps) ranging from 0-2.5e6.  Analytes elute at the following retention times and in 
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the following order: BZP-d7 at 3.72 min, BZP at 3.83 min, FBZP at 4.50 min, MBZP at 
4.70 min, MeOPP at 5.11 min, pFPP at 5.34 min, mCPP-d8 at 5.79 min, mCPP at 5.80 min, 
DCPP at 6.10 min, TFMPP at 6.13 min, and TFMPP-d4 at 6.13 min.  
 
 
3.2 Method Validation  
3.2.1 Calibration Model  
 
 Calibration curves containing all analytes were run a total of five times for both 
matrices.  The working range was 20 ng/mL to 2000 ng/mL for all analytes in both blood 
and urine, except for BZP in urine which was 50 ng/mL to 2000 ng/mL.  BZP, FBZP and 
MBZP were quantified using BZP-d7.  MeOPP, pFPP, mCPP, and DCPP were quantified 
using mCPP-d8.  TFMPP was quantified using TFMPP-d4.  All calibration curves were 
plotted as a linear regression of concentration versus peak area ratio (the ratio between the 
peak area of the analyte and peak area of internal standard) using a weighting factor of 1/x. 
The R2 value for all calibration curves for each analyte was above the minimum accepted 
value of 0.98.  
 
Table 8: R2 Values for Five Calibration Curve Runs of all Analytes in Blood. 
   
Analyte Run 1 Run 2 Run 3 Run 4 Run 5 Average 
BZP 0.9996 0.9988 0.9998 0.9997 0.9990 0.9994 
FBZP 0.9986 0.9996 0.9991 0.9990 0.9999 0.9992 
MBZP 0.9969 0.9971 0.9994 0.9979 0.9994 0.9981 
MeOPP 0.9990 0.9999 0.9995 0.9992 0.9994 0.9994 
pFPP 0.9966 0.9980 0.9947 0.9954 0.9961 0.9962 
mCPP 0.9999 0.9997 0.9995 0.9999 0.9998 0.9998 
DCPP 0.9981 0.9988 0.9993 0.9997 0.9993 0.9990 
TFMPP 0.9992 0.9984 0.9963 0.9972 0.9973 0.9977 
 
  
 
40 
Table 9: R2 Values for Five Calibration Curve Runs of all Analytes in Urine.   
Analyte Run 1 Run 2 Run 3 Run 4 Run 5 Average 
BZP 0.9996 0.9999 0.9996 0.9991 0.9987 0.9994 
FBZP 0.9995 0.9996 0.9997 0.9982 0.9991 0.9992 
MBZP 0.9993 0.9966 0.9968 0.9996 0.9983 0.9981 
MeOPP 0.9997 0.9989 0.9998 0.9991 0.9994 0.9994 
pFPP 0.9978 0.9945 0.9965 0.9945 0.9962 0.9959 
mCPP 0.9999 0.9989 0.9999 0.9997 0.9996 0.9996 
DCPP 0.9996 0.9995 0.9996 0.9990 0.9998 0.9995 
TFMPP 0.9984 0.9959 0.9930 0.9952 0.9970 0.9959 
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3.2.2 Limit of Detection and Quantitation  
 For this study, the limit of detection was determined to be equal to the limit of 
quantitation. The limit of quantitation (LOQ) was determined as the lowest concentration 
that could be quantified within ±20% accuracy using the previously outlined calibration 
model.  Although the LOQ for blood and urine were similar, different values were obtained. 
The LOQ for each analyte was established in three different sources of matrix for both 
blood and urine. Each sample was run three times.  
 The limit of quantitation for analytes in blood was determined to be 10 ng/mL for 
mCPP and TFMPP and 20 ng/mL for BZP, FBZP, MBZP, MeOPP, pFPP, and DCPP. The 
limit of quantitation for analytes in urine was determined to be 10 ng/mL for MeOPP, 
mCPP, TFMPP, and DCPP, 20 ng/mL for FBZP, MBZP and pFPP, and 50 ng/mL for BZP.  
 
3.2.3 Carryover  
 Analyte signal was monitored in double blanks (matrix samples that were not 
fortified with analytes or internal standard) that were run after samples with analyte 
concentrations of 3000, 3500, 4000, 4500, and 5000 ng/mL.  No carryover was observed 
in any of the blanks for either matrix. It was observed that baseline noise increased with 
increasing concentration.  Although there was some signal for pFPP fragment 1 and FBZP 
fragments 1 and 2 in the double blanks of blood and urine, they were determined to be from 
the matrix rather than carryover (see section 3.2.7 for more information). Of the 
concentrations evaluated, 5000 ng/mL was determined to be the highest concentration that 
will not produce carryover in subsequent samples for both blood and urine. 
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3.2.4 Bias and Precision  
Concentrations of 50 ng/mL, 200 ng/mL, and 700 ng/mL were evaluated for bias 
and precision studies in both matrices.  Each concentration sample was prepared in 
triplicate and each replicate was run five times.  From the data, bias and precision were 
calculated as percentages.  Bias is a measure of how close the calculated value is to the true 
nominal value and precision is a measure of reproducibility.  Between-run precision is the 
precision between all replicates and runs at a given concentration.  The within-run precision 
is the precision between the three replicates within a single run at a given concentration.  
This is calculated independently for each of the five runs.  According to SWGTOX 
guidelines, the bias and precision values should not exceed ±20% at each concentration 
(36).  
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Table 10:  Bias and Between-Run Precision Results for all Analytes in Blood.  
 Mean 
(ng/mL) 
STDEV 
(ng/mL) 
Bias 
(%) 
CV 
(%) 
50 ng/mL     
BZP  50.85 3.10 1.71 6.09 
FBZP  50.49 2.53 0.98 5.02 
MBZP  47.65 1.72 -4.70 3.60 
MeOPP  56.57 2.77 13.14 4.89 
pFPP  49.16 3.42 -1.68 6.96 
mCPP  56.45 1.17 12.90 2.08 
TFMPP  53.09 1.14 6.18 2.15 
DCPP  53.12 3.08 6.24 5.81 
200 ng/mL     
BZP  205.78 7.49 2.89 3.64 
FBZP  223.95 5.20 11.97 2.32 
MBZP  191.16 7.28 -4.42 3.81 
MeOPP  210.98 5.71 5.49 2.71 
pFPP  210.69 4.27 5.35 2.03 
mCPP  208.11 3.04 4.05 1.46 
TFMPP  234.15 3.14 17.07 1.34 
DCPP  225.17 6.25 12.58 2.77 
700 ng/mL     
BZP  711.18 23.13 1.60 3.25 
FBZP  716.55 23.35 2.36 3.26 
MBZP  673.26 27.78 -3.82 4.13 
MeOPP  713.42 14.69 1.92 2.06 
pFPP  717.90 22.80 2.56 3.18 
mCPP  730.97 13.02 4.42 1.78 
TFMPP  775.40 8.77 10.77 1.13 
DCPP  714.12 30.21 2.017 4.23 
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Table 11:  Bias and Between-Run Precision Results for all Analytes in Urine.  
 
 Mean 
(ng/mL) 
STDEV 
(ng/mL) 
Bias 
(%) 
CV 
(%) 
50 ng/mL     
BZP  51.42 3.38 2.84 6.57 
FBZP  49.89 2.64 -0.21 5.28 
MBZP  53.18 2.67 6.35 5.01 
MeOPP  55.16 1.49 10.32 2.70 
pFPP  51.65 1.76 3.30 3.42 
mCPP  57.60 1.30 15.19 2.26 
TFMPP  53.24 1.12 6.48 2.10 
DCPP  43.49 2.12 -13.01 4.89 
200 ng/mL     
BZP  200.23 11.15 0.12 5.57 
FBZP  214.34 10.71 7.17 5.00 
MBZP  199.56 19.80 -0.22 9.92 
MeOPP  212.97 4.67 6.48 2.19 
pFPP  220.83 6.75 10.41 3.06 
mCPP  203.35 2.71 1.67 1.33 
TFMPP  214.32 3.09 7.16 1.44 
DCPP  182.63 4.87 -8.69 2.66 
700 ng/mL     
BZP  689.51 20.42 -1.50 2.96 
FBZP  768.59 54.41 9.80 7.08 
MBZP  701.81 61.64 0.26 8.78 
MeOPP  736.48 37.23 5.21 5.06 
pFPP  717.05 29.32 2.44 4.09 
mCPP  723.74 11.32 3.39 1.56 
TFMPP  761.34 13.77 8.76 1.81 
DCPP  674.12 36.91 -3.70 5.47 
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Table 12:  Within-Run Precision Results for all Analytes in Blood.  
 
 % CV 
Run 1 
% CV 
Run 2 
% CV 
Run 3 
% CV 
Run 4 
% CV 
Run 5 
50 ng/mL      
BZP  5.79 2.41 8.47 6.09 5.36 
FBZP  7.36 3.73 3.21 3.83 7.76 
MBZP  2.59 3.43 4.92 1.38 4.92 
MeOPP  4.56 6.17 5.18 7.39 2.07 
pFPP  9.83 6.62 8.60 6.91 7.66 
mCPP  2.55 2.11 2.98 1.22 2.18 
TFMPP  3.59 2.86 1.24 0.43 2.62 
DCPP  7.16 7.53 4.98 6.41 6.87 
200 ng/mL      
BZP  6.07 4.28 3.81 3.24 3.04 
FBZP  2.36 4.11 2.23 2.13 1.46 
MBZP  2.99 3.73 5.80 3.56 5.07 
MeOPP  0.93 3.46 4.73 3.55 1.03 
pFPP  1.55 3.32 1.40 1.65 1.36 
mCPP  2.00 0.64 2.21 1.80 0.69 
TFMPP  0.33 1.50 1.17 2.47 1.30 
DCPP  1.08 2.61 4.27 3.74 1.25 
700 ng/mL      
BZP  2.51 1.28 3.47 4.35 3.26 
FBZP  3.00 1.02 1.04 5.04 4.80 
MBZP  1.42 5.50 4.36 5.54 4.12 
MeOPP  1.86 1.68 2.45 1.57 1.31 
pFPP  2.29 1.42 4.49 4.66 3.87 
mCPP  0.87 1.29 2.68 2.30 1.31 
TFMPP  0.41 0.92 1.62 1.07 1.25 
DCPP  6.36 5.49 3.52 3.86 4.68 
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Table 13:  Within-Run Precision Results for all Analytes in Urine.  
 
 % CV 
Run 1 
% CV 
Run 2 
% CV 
Run 3 
% CV 
Run 4 
% CV 
Run 5 
50 ng/mL      
BZP  5.14 10.27 8.29 7.20 5.06 
FBZP  7.63 5.43 4.37 4.19 3.10 
MBZP  2.55 5.02 3.04 7.34 4.38 
MeOPP  2.45 3.71 1.66 2.60 3.12 
pFPP  2.67 3.88 2.06 1.06 6.57 
mCPP  2.65 0.64 1.18 3.32 1.12 
TFMPP  1.29 1.07 3.85 2.71 2.10 
DCPP  3.31 5.10 4.05 4.84 7.85 
200 ng/mL      
BZP  9.25 3.85 4.14 4.64 7.02 
FBZP  5.72 3.07 2.89 2.98 6.97 
MBZP  5.96 13.85 7.56 11.80 12.85 
MeOPP  0.77 3.47 2.61 2.10 2.30 
pFPP  2.19 3.11 1.64 4.10 4.58 
mCPP  1.57 2.52 0.67 1.05 0.91 
TFMPP  1.28 1.72 0.92 1.13 0.81 
DCPP  3.80 2.62 3.74 2.39 2.94 
700 ng/mL      
BZP  1.61 3.56 1.12 4.33 3.81 
FBZP  8.97 8.01 4.84 9.11 9.21 
MBZP  9.89 8.99 7.97 11.14 12.24 
MeOPP  1.06 2.56 7.81 1.70 4.79 
pFPP  2.93 2.57 8.32 3.45 1.12 
mCPP  0.20 1.43 2.18 1.83 1.17 
TFMPP  0.69 2.08 3.21 1.08 1.04 
DCPP  3.85 5.15 9.85 4.68 6.40 
 
 
3.2.5 Extraction Recovery  
 Concentrations of 50 ng/mL and 200 ng/mL were evaluated for each matrix to 
determine the percentage of each analyte that is recovered after solid phase extraction.  
Extraction recovery was determined by calculating the ratio of peak areas between a set of 
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matrix samples that were fortified with the analytes before extraction and after extraction.  
Extraction recovery was calculated individually at each concentration in both matrices.  
 
Table 14:  Extraction Recovery Results for all Analytes in Blood.   
 
 Fortified Pre-
Extraction: Mean 
Peak Area  
Fortified Post-
Extraction: Mean 
Peak Area  
Extraction 
Recovery 
 (%) 
50 ng/mL    
BZP  49506.64 100574.50 49.22 
FBZP  69437.32 126696.01 54.81 
MBZP  83196.72 113365.07 73.39 
MeOPP  53160.10 66569.28 79.86 
pFPP  402524.66 443868.00 90.69 
mCPP  179336.28 221294.12 81.04 
TFMPP  534215.45 652792.97 81.84 
DCPP  137392.84 184004.59 74.67 
200 ng/mL     
BZP  337029.15 558076.80 60.39 
FBZP  433672.55 723129.15 59.97 
MBZP  793814.20 929206.57 85.43 
MeOPP  439341.29 417417.28 105.25 
pFPP  1896393.38 1989360.35 95.33 
mCPP  875212.35 1005425.64 87.05 
TFMPP  2471699.91 2872338.38 86.05 
DCPP  741310.95 920042.46 80.57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
Table 15:  Extraction Recovery Results for all Analytes in Urine.   
 
 Fortified Pre-
Extraction: Mean 
Peak Area  
Fortified Post-
Extraction: Mean 
Peak Area  
Extraction 
Recovery  
(%) 
50 ng/mL    
BZP  73160.28 119204.25 61.37 
FBZP  88438.73 142344.68 62.13 
MBZP  71296.22 105594.79 67.52 
MeOPP  178291.49 255814.58 69.70 
pFPP  433621.02 641837.50 67.56 
mCPP  165638.87 254696.52 65.03 
TFMPP  431510.00 639308.99 67.50 
DCPP  102430.01 171993.42 59.55 
200 ng/mL    
BZP  470651.30 709099.77 66.37 
FBZP  559734.56 821317.53 68.15 
MBZP  670798.81 706209.25 94.99 
MeOPP  980504.29 1128417.39 86.89 
pFPP  2098058.39 2449645.42 85.65 
mCPP  862518.72 1039897.15 82.94 
TFMPP  2081598.56 2355891.02 88.36 
DCPP  592097.60 709301.69 83.48 
 
        
 
3.2.6 Ionization Suppression/Enhancement    
 
 Ionization suppression/enhancement was assessed at a low concentration of 50 ng/mL 
and a high concentration of 1000 ng/mL.  Neat standards of each concentration were 
prepared and run six times.  These samples are “Set 1”.  Ten matrix samples were prepared 
in duplicate, prepared by solid phase extraction and were fortified with analytes after 
elution at the same two concentrations of 50 ng/mL and 1000 ng/mL.  These samples are 
“Set 2”. The ten matrix sources consisted of pristine blood, pristine urine, postmortem 
blood, postmortem urine, pristine plasma, and pristine serum.  Matrix suppressed the signal 
of the eight analytes in all cases, which is shown by the negative percent values in Table 
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16. Furthermore, the degree of suppression was higher for the lower concentration than the 
high concentration.  There was no correlation between peak area of set 2 and the condition 
or type of matrix.  
 
 
Table 16: Ionization Suppression/Enhancement Results  
 
Analyte 
Mean Peak Area 
Set 1 
Mean Peak Area 
Set 2 
Ionization 
Suppression (%) 
50 ng/mL    
BZP 187917.8 3792426 -95.0449 
FBZP 194426.6 3674646 -94.709 
MBZP 226483.6 3653519 -93.8009 
MeOPP 210504.5 907541.2 -76.805 
pFPP 515474.1 1897533 -72.8345 
mCPP 251360 1067504 -76.4535 
TFMPP 581310.5 2584029 -77.5037 
DCPP 158858.4 936253.6 -83.0325 
1000 ng/mL    
BZP 11768926 47238403 -75.0861 
FBZP 11922103 39889793 -70.1124 
MBZP 12064160 40404215 -70.1413 
MeOPP 4999401 10806161 -53.7356 
pFPP 9305722 17199410 -45.8951 
mCPP 5241555 11945759 -56.122 
TFMPP 11106015 22850913 -51.3979 
DCPP 3928382 10179897 -61.4104 
      
 
3.2.7 Matrix Effects 
 
 Ten matrix specimens were analyzed without addition of analytes or internal 
standard.  The signal of the analytes were monitored to determine if any matrix components 
or interferences exist that would cause chromatographic peaks to appear during the time 
course of the method.  This study used ten different matrix sources of varying types and 
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conditions.  The four sources obtained from the Federal Aviation Administration may have 
contained other drugs in them.  Peaks corresponding to the FBZP 1 (195.2/109.1 Da) 
fragment were observed in all of the blood, serum, and plasma blanks at a retention time 
of 5.4 minutes.  Peaks corresponding to BZP-d7 (184.3/98.2 Da) were urine-specific and 
had a retention time of 4.65 min.  Peaks corresponding to FBZP 2 (195.2/83.2 Da) and 
pFPP 1 (181.2/138.2 Da) fragment ions were observed in all ten matrix specimens and had 
retention times of 5.4 min and 4.65 min, respectively.  pFPP 1 also appeared in FAA-5 at 
1.9 and 4.15 min.  Peaks corresponding to mCPP 1 (197.1/154.2 Da) fragments were only 
observed in the pristine urine specimens (2/3 urine specimens) and had a retention time of 
5.1 minutes.  
 
Table 17: Summary of Observed Matrix Interferences. This table shows the retention 
time (min) of signals produced by the ten matrix specimens and the ion at which it was 
being detected.  PM refers to postmortem.  
 
Matrix  Type FBZP 1 
(195.2/109.1) 
FBZP 2 
(195.21/83.2) 
pFPP 1 
(181.2/138.2) 
mCPP 1 
(197.1/154.2) 
BZP-d7 
(184.3/98.2) 
B1086  Blood 5.4 5.4 4.65   
B0786  Blood 5.4 5.4 4.65   
FAA-5  PM 
Blood 
5.4 5.4 
1.9, 4.15, 
4.65 
  
FAA-
6B 
PM 
Blood 
5.4 5.4 4.65   
FAA-7 PM 
Blood 
5.4 5.4 4.65   
B1151 Serum 5.4 5.4 4.65   
B1150 Plasma 5.4 5.4 4.65   
B1085 Urine  5.4 4.65 5.1 4.65 
B0683 Urine  5.4 4.65 5.1 4.65 
FAA-
6U 
PM 
Urine 
 5.4 4.65  4.65 
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3.2.8 Interferences  
 A study to observe any stable isotope interferences was completed. In this study, 
analytes were prepared in ten different matrix sources without the addition of internal 
standard.  Also, the ten matrix sources were prepared with internal standard but without 
any of the analytes.  The analyte signal was monitored in each of the two sets of samples.  
No interferences were detected as a result of the internal standards in any of the samples 
analyzed.  
 In an experiment to determine possible interferences from other sources, fourteen 
different drugs were prepared in solution at a concentration of 1000 ng/mL and run on the 
method in the absence of the analytes.  In addition, these drugs were prepared in the 
presence of the eight analytes with all drugs in solution at a concentration of 1000 ng/mL.  
Internal standard was added to these samples.  Acetaminophen, alprazolam, amphetamine, 
hydrocodone, lidocaine, MDA, MDMA, methamphetamine, morphine, nicotine and (-)-
11-nor-9-carboxy-delta9-THC did not have any effect on the analytes and did not cause 
any spikes in signal during the chromatographic method.  
 Caffeine, DBZP, and pCPP did cause spikes in signal during the method.  At 1000 
ng/mL without matrix, caffeine produced a chromatographic peak having intensity of about 
1.6e5 cps with the fragment ions corresponding to FBZP 1 (195.2/109.1 Da) and FBZP 2 
(195.2/83.2 Da).  This peak had a retention time of 5.38 min, which differs from the actual 
FBZP retention time of 4.50 min.  At 1000 ng/mL without matrix, DBZP produced a 
chromatographic peak having intensity of about 3.2e4 cps with the fragment ions 
corresponding to BZP 1 (177.1/91.1 Da) and BZP 2 (177.1/65.1 Da).  This peak had a 
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retention time of 6.13 min, which differs from the actual BZP retention time of 3.83 min.  
At 1000 ng/mL without matrix, pCPP produced a chromatographic peak having intensity 
of about 4.7e6 cps at 5.79 min and major ions of (197.1/154.2 and 197.1/118.2 Da).  The 
retention time and both fragments are characteristic of mCPP.  When these drugs were run 
in the presence of the analytes, caffeine and DBZP did not impact the signal or peak area 
of any analytes.  It was determined that pCPP increased the peak area of the mCPP peak 
by almost 50%, while all other analytes were unaffected.  
 Through this research, it was found that DCPP has a stable isotope which may 
interfere with TFMPP confirmation and quantitation. Due to the two chlorine atoms in the 
molecule, DCPP has three isotopic states with mass-to-charge values of 231, 232 and 233 
Da. All three isotopes were optimized. The 231 Da isotope exhibited the greatest intensity; 
however, it could not be used as it had the same precursor and major product ion masses 
as TFMPP.  The product ions of the 232 Da isotope exhibited very low intensity causing 
quantitation to be less robust and reliable. The 233 Da isotope was chosen for the method 
as it produced high intensity product ions and was able to be distinguished from TFMPP.  
When TFMPP is run on the method alone, DCPP remains undetected.  When DCPP is run 
on the method alone, an intense TFMPP peak showing both TFMPP fragment ions is 
observed.  The Q1 MS scan for DCPP and the extracted ion chromatograms of TFMPP and 
DCPP when run individually are shown in figures 5, 6 and 7.  
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Figure 5: Q1 MS Scan of DCPP. This scan shows mass-to-charge ratios in Da on the x-
axis and intensity in counts per second on the y-axis.  
 
 
 
 
Figure 6: Chromatogram of TFMPP When Run Alone at a Concentration of 500 
ng/mL in Solution.  
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Figure 7: Chromatogram of DCPP When Run Alone at a Concentration of 500 ng/mL 
in Solution. 
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4. DISCUSSION 
4.1 Detection of Analytes  
 Analytes were chosen based off of appearance in the literature as having been abused 
or having the potential for abuse, as well as the availability of the drugs for purchase.  
MDBP, BZP’s methylenedioxy analog, is another commonly abused synthetic piperazine; 
however, it was not readily available and could not be included in this method.   
 All analytes were able to be detected using this method.  Two fragments were 
included in the MRM table for each analyte so that the ion with the best signal-to-noise 
ratio could be used for quantitation and the second ion could be used for confirmation of 
the analyte.  The phenyl-piperazine compounds typically had better peak shape and 
resolution than the benzyl-piperazines, which exhibited tailing and broader peaks.  When 
developing the method, different pH mobile phases were investigated to reduce some of 
the tailing.  The 2mM ammonium formate buffer with 0.2% formic acid at a pH of about 
2.68 provided the best results.  
 All compounds elute within the 6.5 min mass scan time, with a total method length 
of 11.5 minutes with equilibrations. An analysis of analyte retention times revealed very 
little variation. BZP had the highest standard deviation and percent variation at only 0.006 
and 0.147, respectively.  
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4.2 Method Validation 
4.2.1 Validation Parameters  
 The working range of the calibration model was the range of concentrations that 
produced the best linear regression and most accurately calculated concentrations of 
unknowns.  Calibration curves were plotted as a linear regression of concentration versus 
peak area ratio with a weighting factor of 1/x.  Since high concentration samples have 
greater variance factors than low concentration samples, this weighting factor was applied 
to all curves so that all concentration samples were given a more equal weighting in the 
regression line.  Lower concentration samples were calculated with greater accuracy when 
this weighting factor was applied. 
 For this study, the limit of detection equaled the limit of quantitation.  Although 
signal for all analytes was observed at concentrations lower than the determined LOQ, the 
peak areas did not produce calculated concentrations that were within the maximum 
acceptable bias of ±20%.  BZP in urine had the highest LOQ at 50 ng/mL.  The peak tailing 
and broad peak shape of this compound resulted in inaccurate calculated concentration 
values below 50 ng/mL.  
 The highest concentration evaluated for carryover was 5000 ng/mL.  This sample 
was prepared once in each matrix and both samples were run three times.  Double blanks 
were analyzed immediately after each 5000 ng/mL sample.  No carryover was detected in 
any of the double blanks that followed these high concentration samples for either matrix. 
Quantitation was attempted for this concentration using the previously established 
calibration model.  All calculated values fell below a 20% bias limit, with calculated 
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concentrations ranging from roughly 2400 to 4000 ng/mL, depending on the analyte.  This 
suggests that 5000 ng/mL is above the upper limit of quantitation with this calibration 
model and all unknowns calculated above 2400 ng/mL (the highest calibrator of 2000 
ng/mL with a +20% bias) should be diluted for analysis.  
 The bias and precision assessment revealed a % bias and % CV lower than 20% for 
all analytes at all concentrations.  This shows that the method is both accurate and precise 
at calculating unknown concentrations.  Similar values of % bias and % CV were obtained 
at each concentration.  This shows that low, medium and high concentrations can all be 
accurately determined and one concentration range does not produce better accuracy or 
precision over another.  
  The extraction recovery assessment was performed to evaluate the efficiency of the 
solid phase extraction procedure.  An inevitable loss of analyte occurs with sample 
preparation.  It may be that some of the analytes are unintentionally eluted from the column 
during the wash steps or that some of the analytes are not eluted at all.  The purpose of this 
study was to determine the percentage of analyte that is recovered following the extraction 
procedure.  There was a correlation between concentration and analyte type with percent 
recovery.  It was observed that the 200 ng/mL samples had higher percent recoveries than 
the 50 ng/mL samples.  Also, the three benzyl-piperazines had lower percent recoveries 
than the five phenyl-piperazines.  These patterns were observed in both matrices.  Samples 
prepared in blood and urine produced very similar percent recoveries, which suggests the 
extraction procedure works equally well for blood and urine.  
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 The ionization suppression/enhancement study was conducted to determine the 
amount that ions are suppressed or enhanced when in the presence of a matrix.  Results 
show extremely high suppression for all analytes at both concentrations.  No ionization 
enhancement was observed.  It was also found that there was a higher degree of suppression 
at the 50 ng/mL concentration than the 1000 ng/mL concentration and the benzyl-
piperazines exhibited a higher degree of suppression than the phenyl-piperazines. There 
was no correlation between matrix type and the degree of suppression.  Although 
suppression was high, it did not affect the other validation parameters. The limit of 
quantitation was found using the same matrices used in this study which illustrates that the 
LOQ is reliable given the observed matrix effects.  
 Signal was observed when the ten different sources of matrix were run on the method 
without any analytes or internal standard, indicating the presence of matrix effects.  The 
results showed some interferences that are blood/serum/plasma specific and some that are 
urine specific.  Others were observed in all ten of the matrix samples.  The condition of the 
matrix sample did not seem to have an effect on the matrix interferences observed.  The 
effects presented themselves as FBZP 1, FBZP 2, pFPP 1, BZP-d7, and mCPP 1 fragment 
ions and each had a specific retention time that was different than the actual piperazine 
drug they were being detected as.  They were also present at relatively low intensities. 
These matrix effects are considered benign since analyte detection and quantitation was 
not impacted by their presence.  
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4.2.2 Interferences from Other Commonly Found Analytes  
 The drugs incorporated in the interference study were chosen based off of what drugs 
are normally found with synthetic piperazines, whether it be adulterants, impurities, 
isomers, or other controlled substances used in combination with synthetic piperazines (2, 
10, 20, 24).  The other consideration was which drugs were available in the laboratory for 
use.  Literature shows that these designer drugs are most commonly used in combination 
with cannabis, nicotine and amphetamines.  The para-form of chlorophenyl-piperazine 
(pCPP) was included to assess the method’s ability to differentiate between isomeric pairs 
and DBZP was included because it is often found in samples as an impurity of BZP 
synthesis.  Acetaminophen, lidocaine, and caffeine were incorporated as they are common 
adulterants.  Alprazolam, hydrocodone and morphine were included since benzodiazepines 
and opiates are commonly used drugs.  Of these fourteen drugs, caffeine, DBZP and pCPP 
were the only compounds that elicited a response in the chromatogram.  Caffeine was 
detected by the method as FBZP and DBZP was being detected as BZP.  Both fragments 
were present in both peaks.  These peaks were observed at low intensities in comparison 
to the analytes and had retention times different than actual FBZP and BZP compounds, 
making them very distinguishable.  It can be concluded that caffeine and DBZP did not 
interfere with the detection or quantitation of any of the analytes.  However, when pCPP 
was run on the method, a high intensity peak was observed at the same retention time as 
mCPP.  When pCPP was run in the presence of the analytes at the same concentration, it 
was found that the peak area of mCPP doubled.  This illustrates that the method cannot 
differentiate between isomeric pairs.  
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4.2.3 Interferences with TFMPP 
 Through the course of the validation studies, several potential interferences to 
TFMPP were identified.  First, all solvent blanks showed a spike in signal that is identified 
as TFMPP 1 (231.1/188.1 Da).  The intensity of the peak was the same in every run and 
was approximately 4e4 cps.  It had a similar, yet slightly different retention time to TFMPP.  
Where TFMPP reproducibly elutes at about 6.13, this extraneous peak elutes at 6.35min.  
Fresh solvents were used for sample preparation and fresh mobile phases were prepared 
before every run.  LC grade water was used to prepare mobile phases.  Security guard 
cartridges were replaced approximately every 150 runs, or as needed.  In addition, the 
column was flushed with a changing column solution consisting of acetonitrile and 
isopropanol after every use.  Since only one of the TFMPP fragments was detected, the 
retention time was different and the intensity of the peak is relatively unchanging, it was 
determined that the peak is most likely the result of some other contamination rather than 
carryover or contamination from TFMPP itself.  In an attempt to determine the cause of 
this peak, an Enhanced MS scan was run using the method parameters.  At the time of 
TFMPP elution, activity from very high molecular weight species was observed.  Ions with 
mass-to-charge ratios ranging from 500-700 Da were present at intensities of about 5e7.  
One hypothesis to explain the signal is that polymers were present in the LCMS and were 
breaking down to molecular weights similar to TFMPP’s precursor and product ion.  
Regardless of the source, this peak was determined to be below TFMPP’s limit of 
quantitation and did not seem to negatively impact the validation results.  Therefore, it was 
determined that this peak seen in all sample types is insignificant.  
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Figure 8: Solvent Blank Showing Large “TFMPP 1” Peak at approximately 6.35 min. 
 
  
 
 
Figure 9: Total Ion Chromatogram of a Methanol Blank When in Enhanced MS Scan 
Mode. The x-axis is time and ranges from 0-5 minutes. The y-axis is intensity in cps and 
extends to a peak intensity of 7.3e7 cps. The intensity remains at about 8e6 cps for the 
majority of the scan.  
 
TFMPP 1 
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Figure 10: Mass Spectrum During an Enhanced MS Scan of the Method. The x-axis 
is mass-to-charge ratios in Da and the y-axis is intensity in cps. The intensity maximum is 
5.6e7.  
 
 The other potential interference to TFMPP is the analyte DCPP. This compound has 
a stable isotope with the same mass-to-charge ratio as TFMPP.  Furthermore, TFMPP and 
this isotope of DCPP both produce high intensity fragment ions with the same mass-to-
charge ratio.  Although DCPP and TFMPP coelute, quantitation of either compound was 
not affected during validation studies.  This may be because all samples were prepared 
when TFMPP was in the presence of DCPP.  By following this preparation, the ratios 
between the internal standard and the calibrators and the ratios between the internal 
standard and unknowns were always constant.  As illustrated by Figure 7, when DCPP is 
run alone, both TFMPP fragments are “detected” due to DCPP’s other stable isotope.  This 
suggests that if a calibration curve was prepared with all analytes (TFMPP in the presence 
of DCPP) and a sample only containing TFMPP was analyzed, the calculated concentration 
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may be different than the actual value since it is not receiving any influence from the DCPP 
isotope.  Therefore, the influence that DCPP has on the calculated concentration of TFMPP 
unknowns should be investigated further.  Caution should also be taken when using other 
published detection methods to identify TFMPP in case samples.  If those methods also 
use the 231/188 and 231/118 TFMPP fragments, DCPP may be in the samples and be 
falsely identified as TFMPP.  
 Since DCPP shows false TFMPP detection when it is run alone, the addition of a 
third fragment ion to both compounds in the MRM table may help differentiate between 
samples that only contain DCPP, TFMPP or samples that contain DCPP and TFMPP in 
combination.  Also, the ratios between the fragment peak areas (of TFMPP1, TFMPP2, 
DCPP1, and DCPP2) should be monitored and may be helpful in determining if the signal 
is all from one compound or if there are, in fact, two substances present.   
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5. CONCLUSIONS 
5.1 Summary of Findings  
As is demonstrated by the results of this study, an analytical method was developed 
and validated for both the identification and quantitation of eight synthetic piperazines in 
blood and urine. The total run time was 11.5 minutes with equilibrations.  Calibration 
curves in both matrices exhibited an R2 value > 0.99 with a weighting factor of 1/x.  A 
linear dynamic range of 20-2000 ng/mL was used for all analytes in both matrices, except 
for BZP in urine which ranged from 50-2000 ng/mL.  In blood, the limit of quantitation 
was 10 ng/mL for mCPP and TFMPP and 20 ng/mL for BZP, FBZP, MBZP, MeOPP, pFPP 
and DCPP.  In urine, the limit of quantitation was 10 ng/mL for MeOPP, mCPP, TFMPP 
and DCPP, 20 ng/mL for FBZP, MBZP and pFPP and 50 ng/mL for BZP.  When a 200 
ng/mL concentration was evaluated, the SPE procedure showed percent recoveries ranging 
from 80-95% for blood; except for BZP, FBZP, and MeOPP which had recoveries of 60%, 
60%, and 105%, respectively.  Percent recoveries ranged from 82-94% for urine; except 
for BZP and FBZP which had recoveries of 66% and 68%, respectively.  Bias and precision 
were assessed at concentrations of 50, 200, and 700 ng/mL.  All “unknowns” were 
calculated within ±20% accuracy and within ±20% coefficient of variation.  The highest 
concentration evaluated that did not produce carryover in subsequent matrix blanks was 
5000 ng/mL.  Ionization was suppressed for all analytes in both matrices by 45-95%.  
Matrix effects were present in blood, serum, plasma and urine but were determined to be 
insignificant. No stable isotope interferences from internal standards were detected. Of the 
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analytes, a stable isotope from DCPP was determined to interfere with TFMPP. This 
method produced comparable results between the two matrices.  
Of the drugs evaluated, caffeine, DBZP, and pCPP produced chromatographic 
peaks in the method; however, pCPP was the only substance that effected detection 
quantitation of an analyte. It increased the peak area of mCPP by almost 50% when present 
at the same concentration which suggests this method is unable to differentiate between 
isomeric pairs.  This is beneficial since many countries may also place restrictions on the 
isomers of a controlled drug.   
 
5.2 Significance of Findings  
Many of these substances are new and little has been published on their detection 
in biological specimens and the significance of concentrations that are determined. As 
restrictions continue to be placed on these drugs, more analogs will emerge so it is crucial 
that scientists and law makers stay up to speed with the effects of these drugs and the 
patterns of their use. There is a need for a confirmatory quantitative technique to identify 
the array of abused piperazines in blood and urine using LC-MS/MS. 
This is a sensitive, reliable, and robust method with a wide linear dynamic range to 
account for the presence of these analytes in both blood and urine.  The results of this 
research and this fully validated method can be transferred and used for the identification 
and quantitation of these substances in forensic casework.  
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6. FUTURE DIRECTIONS  
6.1 Method Expansion  
 Once more related compounds become available for purchase, it may be useful to 
expand the method.  Common metabolites of these drugs may be important to incorporate, 
especially since many of them metabolize quickly.  The validation of this method could 
also be extended to include matrices like plasma and serum to allow for wider analysis 
options. 
 
6.2 Stability Studies  
 The stability of these eight analytes when stored in blood and urine should be 
thoroughly investigated.  All analytes should be prepared in both matrices and stored in 
various temperature conditions for various lengths of time to determine how quickly the 
synthetic piperazines degrade in each condition and how degradation will affect detection 
and quantitation.  The effect of freeze-thaw cycles on the specimens should also be 
evaluated.  This study will help the analyst to better interpret the results of this method.  
 
6.3 Additional Interference Studies  
6.3.1 Commonly Used Drugs  
 The interference study could be expanded to include other commonly encountered 
substances such as cocaine, ketamine, and  metabolites (24).  Furthermore, trazodone and 
nefazodone metabolize to mCPP and piberaline metabolizes to BZP (1, 29).  These 
substances, along with other therapeutic piperazine-derived drugs like clozapine and 
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sildenafil, should be tested with this method to see if they pose as interferences (8).  In 
addition, most of the synthetic piperazines in this study have an isomer counterpart.  These 
isomers should be evaluated to determine if the method is able to discriminate between any 
of the isomer pairs and to determine any effects they may have on quantitation.   
 
6.3.2 Effect of DCPP on TFMPP 
 An experiment should be conducted to further inspect the influence of DCPP on the 
quantitation of TFMPP. A calibration curve containing all analytes should be run followed 
by a sample of known concentration that only contains TFMPP and internal standard. If 
TFMPP is calculated correctly, it can be determined that DCPP has no influence or an 
insignificant influence on TFMPP. If TFMPP is calculated incorrectly, it can be concluded 
that DCPP does affect quantitation of TFMPP. If this is the case, this method can still be 
employed; however, a calibration curve only containing TFMPP (or containing TFMPP 
with all analytes except for DCPP) would have to be prepared to accurately calculate the 
concentration of TFMPP in the unknown sample.   
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APPENDIX A: LIMIT OF QUANTITATION CHROMATOGRAPHIC DATA 
 
 
Figure A: 20 ng/mL Sample of All Analytes in Blood.  
 
 
Figure B: A 20 ng/mL Sample of All Analytes in Urine.  
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Figure C: A 50 ng/mL Sample of All Analytes in Urine.  
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APPENDIX B: CARRYOVER STUDY CHROMATOGRAPHIC DATA 
 
Figure A: A 5000 ng/mL Sample of All Analytes in Blood.  
 
 
Figure B: Double Blank (Blood) Following 5000 ng/mL Sample in Blood. No 
carryover detected.  All peaks observed were determined to be from matrix effects or 
were observed in solvent blanks.  
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Figure C: Solvent Blank Following Double Blank of Blood Sample.  
 
 
Figure D: A 5000 ng/mL Sample of All Analytes in Urine.   
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Figure E: Double Blank (Urine) Following a 5000 ng/mL Sample of All Analytes in 
Urine.  No carryover detected.  Observed peaks were determined to be from matrix 
effects or were also observed in all solvent blanks.  
 
 
 
 
 
Figure F: Solvent Blank Following a Double Blank Urine Sample.  
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APPENDIX C: MATRIX EFFECTS STUDY CHROMATOGRAPHIC DATA 
 
 
Figure A: Solvent Blank during Matrix Effects and Interferences Studies. 
Abnormally high baseline noise was observed following the replacement of the MS 
pump.  
 
 
 
 
Figure B: B1086 (Blood) Double Blank Matrix.  
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Figure C: B0786 (Blood) Double Blank matrix.  
 
 
 
 
 
 
Figure D: FAA-5 (Blood) Double Blank Matrix. 
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Figure E: FAA-6B (Blood) Double Blank Matrix.  
 
 
 
 
 
 
Figure F: FAA-7 (Blood) Double Blank Matrix.  
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Figure G: B1151 (Serum) Double Blank Matrix.  
 
 
 
 
 
 
Figure H: B1150 (Defibrinated Plasma) Double Blank Matrix.  
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Figure I: B0683 (Urine) Double Blank Matrix.  
 
 
 
 
 
 
 
Figure J: B1085 (Urine) Double Blank Matrix.  
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Figure K: FAA-6U (Urine) Double Blank Matrix.  
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APPENDIX D: INTERFERENCE STUDY CHROMATOGRAPHIC DATA 
 
 
Figure A: A 1000 ng/mL Sample of Caffeine Only.  The arrow points to the caffeine 
peak. 
 
 
 
 
 
 
Figure B: Caffeine in the Presence of All Analytes.  All analytes, including caffeine are 
present at a concentration of 1000 ng/mL.  The arrow points to the caffeine peak.  
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Figure C: A 1000 ng/mL Sample of DBZP Only.  The arrow points to the DBZP peak.  
 
 
 
 
 
 
Figure D: DBZP in the Presence of All Analytes.  All analytes and DBZP are present at 
a concentration of 1000 ng/mL. The peak corresponding to DBZP is not visible.  
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Figure E: A 1000 ng/mL Sample of pCPP Only.  The arrow points to the pCPP peak 
that is detected as mCPP 1 and 2.  
 
 
 
 
Figure F: pCPP in the Presence of All Analytes.  All analytes and pCPP are present at 
a concentration of 1000 ng/mL.  mCPP peak is larger than usual.  
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APPENDIX E: IONIZATION SUPPRESSION/ENHANCEMENT 
CHROMATOGRAPHIC DATA  
 
 
Figure A: A 50 ng/mL Neat Standard of All Analytes.  
 
 
 
 
 
Figure B: A 50 ng/mL Sample of All Analytes in Urine.  This a representative 
chromatogram of the other 50 ng/mL samples in blank matrix from this study. Severe 
suppression of signal is observed.  
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Figure C: A 1000 ng/mL Neat Standard of All Analytes.  
 
 
 
Figure D: A 1000 ng/mL Sample of All Analytes in Blood.  This a representative 
chromatogram of the other 1000 ng/mL samples in blank matrix from this study.  Severe 
suppression of signal is observed. 
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